flecainide has been researched along with Arrhythmias, Cardiac in 351 studies
Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.
flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).
Arrhythmias, Cardiac: Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Flecainide and propafenone are antiarrhythmic drugs of the class 1C (Vaughan and Williams) commonly used for ventricular arrhythmias." | 10.17 | [Propafenone and flecainide in the therapy of ventricular arrhythmias]. ( Davini, A; Lattanzi, F; Paci, A; Paperini, L; Reisenhofer, B; Squarcini, G; Topi, A; Topi, PL, 1995) |
| " Furthermore, the Cardiac Arrhythmia Pilot Study compared moricizine in postinfarction patients with encainide and flecainide." | 10.16 | Comparisons of efficacy and tolerance of moricizine with other antiarrhythmic agents in the treatment of chronic ventricular arrhythmias. ( Anderson, JL, 1990) |
| "Patients with supraventricular arrhythmias have been safely and effectively treated with flecainide." | 9.08 | Safety and utility of flecainide acetate in the routine care of patients with supraventricular tachyarrhythmias: results of a multicenter trial. The Flecainide Supraventricular Tachycardia Study Group. ( Buxton, AE; Heilman, JM; Hopson, JR; Kienzle, MG; Nademanee, K; Rinkenberger, RL, 1996) |
| "In order to compare the long-term safety of flecainide and propafenone, an open label, randomized, parallel group study was performed in 335 patients with paroxysmal atrial fibrillation (n = 200) or paroxysmal supraventricular tachycardia (n = 135), and no history of heart disease." | 9.08 | Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group. ( Casadei, G; Chimienti, M; Cullen, MT, 1995) |
| "Although active treatment in CAST-I was associated with greater mortality than placebo with respect to almost all baseline variables, the therapeutic hazard was more than expected in patients with non-Q-wave myocardial infarction and (for total mortality) frequent premature VPDs and higher heart rates, suggesting that the adverse effect of encainide or flecainide therapy is greater when ischemic and electrical instability are present." | 9.07 | Interaction of baseline characteristics with the hazard of encainide, flecainide, and moricizine therapy in patients with myocardial infarction. A possible explanation for increased mortality in the Cardiac Arrhythmia Suppression Trial (CAST). ( Anderson, JL; Buckingham, TA; Carlson, MD; Carson, PE; Hallstrom, A; Henthorn, RW; Platia, EV, 1994) |
| "Evaluation of efficacy of intravenous flecainide to revert supraventricular arrhythmias to sinus rhythm in patients with respiratory insufficiency." | 9.07 | Efficacy of flecainide in patients with supraventricular arrhythmias and respiratory insufficiency. ( Barranco, F; Guerrero, M; Rodriguez, J; Sanchez, M, 1994) |
| "The Cardiac Arrhythmia Suppression Trial (CAST) was a multicenter double-blind, placebo-controlled study designed to determine whether suppression of ventricular ectopic activity by means of antiarrhythmic drugs (encainide, flecainide or moricizine) after acute myocardial infarction would reduce the incidence of arrhythmic death." | 9.07 | Circadian pattern of arrhythmic death in patients receiving encainide, flecainide or moricizine in the Cardiac Arrhythmia Suppression Trial (CAST). ( Barker, AH; Brooks, MM; Capone, R; Echt, DS; Greene, HL; Liebson, PR; Mitchell, LB; Peters, RW, 1994) |
| "The efficacy and safety of intravenous flecainide to convert recent-onset atrial fibrillation (AF) (present for greater than or equal to 30 minutes and less than or equal to 72 hours and a ventricular response greater than or equal to 120 beats/min) was investigated." | 9.07 | Efficacy of flecainide for the reversion of acute onset atrial fibrillation. ( Clarke, GM; Coombs, LJ; Dobb, GJ; Donovan, KD; Lee, KY; Murdock, CJ; Weekes, JN, 1992) |
| "In the Cardiac Arrhythmia Suppression Trial, designed to test the hypothesis that suppression of ventricular ectopy after a myocardial infarction reduces the incidence of sudden death, patients in whom ventricular ectopy could be suppressed with encainide, flecainide, or moricizine were randomly assigned to receive either active drug or placebo." | 9.07 | Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. ( Arensberg, D; Baker, A; Barker, AH; Echt, DS; Friedman, L; Greene, HL; Liebson, PR; Mitchell, LB; Obias-Manno, D; Peters, RW, 1991) |
| " The Cardiac Arrhythmia Suppression Trial (CAST) is evaluating the effect of antiarrhythmic therapy (encainide, flecainide, or moricizine) in patients with asymptomatic or mildly symptomatic ventricular arrhythmia (six or more ventricular premature beats per hour) after myocardial infarction." | 9.06 | Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. ( , 1989) |
| "The antiarrhythmic efficacy of intravenous flecainide and intravenous digoxin was assessed in 29 patients (26 men), aged 43 to 73 (63 +/- 7) years who developed atrial arrhythmias in the first 96 hours after coronary artery bypass grafting." | 9.06 | Efficacy of flecainide acetate for atrial arrhythmias following coronary artery bypass grafting. ( Camm, AJ; Parker, DJ; Wafa, SS; Ward, DE, 1989) |
| "The aim of this multicentre study, carried out by the Italian Study Group on the Electrophysiology of Arrhythmias (GISEA) in 60 Italian Cardiology Centres on 260 patients, was to assess the efficacy and the safety of flecainide in the treatment of stable hyperkinetic ventricular arrhythmias (greater than 100 ventricular ectopic beats/hour per day)." | 9.06 | Efficacy and safety of flecainide in patients with stable ventricular ectopic beats. Multicenter trial of the Italian Study Group on the Electrophysiology of Arrhythmias. ( , 1989) |
| "The efficacy and safety of flecainide were studied in the maintenance of sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter." | 9.06 | Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter. ( Crijns, HJ; Hamer, HP; Lie, KI; Van Gelder, IC; Van Gilst, WH; Van Wijk, LM, 1989) |
| "Flecainide, a new antiarrhythmic drug (group 1 according to the classification after Vaughan Williams), is used in the treatment of atrial and ventricular arrhythmias." | 9.06 | [Hemodynamic effects of the anti-arrhythmia agent flecainide (Tambocor) in coronary surgery patients]. ( Boldt, J; Görlach, G; Hempelmann, G; Kling, D; Russ, W, 1987) |
| "The effectiveness and safety of oral flecainide for suppression of complex ventricular arrhythmias was tested in nine patients in a short-term (4 wk), single-blind, placebo-controlled experiment." | 9.05 | Suppression of complex ventricular arrhythmias by oral flecainide. ( Adhar, G; Duran, D; Griffith, LS; Platia, EV; Reid, PR, 1982) |
| "The effects on ventricular arrhythmias of a new class IA drug, flecainide, were compared with those of amiodarone in 10 patients with frequent, chronic, and stable ventricular ectopic beats (VEBs)." | 9.05 | Efficacy of flecainide in the management of ventricular arrhythmias: comparative study with amiodarone. ( Bertolasi, CA; Dubner, SJ; Elencwajg, BD; Mendelzon, R; Palma, S; Ramos, A, 1985) |
| "The aim of this review is to evaluate the available data on efficacy and safety of flecainide in all the spectrum of its indications including cardioversion of recent-onset AF, sinus rhythm maintenance in paroxysmal AF and management of ventricular tachyarrhythmias." | 8.89 | Flecainide acetate for the treatment of atrial and ventricular arrhythmias. ( Apostolakis, S; Breithardt, G; Fabritz, L; Kirchhof, P; Oeff, M; Tebbe, U, 2013) |
| "Flecainide (CAS 54143-55-4) has been associated with increased mortality in patients with ventricular dysfunction and arrhythmias." | 8.81 | Meta-analysis of flecainide safety in patients with supraventricular arrhythmias. ( Wehling, M, 2002) |
| "This report summarizes efficacy and safety data on the use of flecainide acetate for supraventricular arrhythmias." | 8.78 | Short- and long-term efficacy and safety of flecainide acetate for supraventricular arrhythmias. ( Hohnloser, SH; Zabel, M, 1992) |
| "The effects of flecainide on electrophysiologic parameters and arrhythmias in the Wolff-Parkinson-White syndrome were reviewed." | 8.78 | Flecainide in the Wolff-Parkinson-White syndrome. ( Crozier, I, 1992) |
| "Flecainide is a benzenacetamide synthesised about a decade ago and only recently introduced into the treatment of arrhythmias." | 8.77 | [Flecainide and anti-arrhythmia therapy]. ( Croce, L; Lomuscio, A; Pozzoni, L; Romano, S, 1988) |
| "Sotalol and flecainide are used as second line agents in children for the treatment of supraventricular arrhythmias (SA) refractory to anti-beta adrenergic antiarrhythmics or digoxin." | 8.02 | "Second line medications" for supraventricular arrhythmias in children: In-hospital efficacy and adverse events during treatment initiation of sotalol and flecainide. ( Kahr, PC; Kim, JJ; Miyake, CY; Moffett, BS; Valdes, SO, 2021) |
| "Although flecainide has a risk of proarrhythmia in patients with structural heart disease, its mechanism has been mainly ascribed to use-dependency and a rapid ventricular response to organized atrial tachyarrhythmias or to ventricular tachycardia." | 7.79 | Flecainide-associated bradycardia-dependent torsade de pointes: another potential mechanism of proarrhythmia. ( Kim, HS; Kim, SS; Pak, HN; Park, JS, 2013) |
| "Thirty-three patients received flecainide because of exercise-induced ventricular arrhythmias despite conventional (for different reasons, not always optimal) therapy (median age 25 years; range 7 to 68 years; 73% female)." | 7.77 | Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. ( Bhuiyan, ZA; Fish, FA; Haïssaguerre, M; Kannankeril, PJ; Knollmann, BC; Krahn, AD; Laborderie, J; Leenhardt, A; Sacher, F; Shimizu, W; Sumitomo, N; van der Veen, MJ; van der Werf, C; Viskin, S; Watanabe, H; Wilde, AA; Willems, AR, 2011) |
| "To assess the safety of long-term treatment with flecainide in patients with atrial fibrillation (AF), particularly with regard to sudden cardiac death (SCD) and proarrhythmic events." | 7.77 | The safety of flecainide treatment of atrial fibrillation: long-term incidence of sudden cardiac death and proarrhythmic events. ( Almroth, H; Andersson, T; Englund, A; Fengsrud, E; Friberg, L; Linde, P; Rosenqvist, M, 2011) |
| " flecainide has a high efficacy for the treatment of experimentally-induced acute atrial fibrillation (AF) in horses and that its use is associated with minimal toxic side effects." | 7.72 | Use of intravenous flecainide in horses with naturally-occurring atrial fibrillation. ( Blissitt, KJ; Keen, JA; van Loon, G; Young, LE, 2004) |
| "We have linked 2 inactivation gating defects ("closed-state" fast inactivation and intermediate inactivation) to flecainide sensitivity in patients carrying LQT3 and Brugada syndrome mutations." | 7.71 | Gating-dependent mechanisms for flecainide action in SCN5A-linked arrhythmia syndromes. ( Balser, JR; Bezzina, CR; George, AL; Roden, DM; Viswanathan, PC; Wilde, AA, 2001) |
| "We investigated effects of a new Na+ channel blocking antiarrhythmic drug, A-2545, N-3 (2,2,5,5-tetramethyl-3-pyrroline-3-carboxamido)-propyl-phthalimide-hydro chloride, on various canine ventricular automaticity arrhythmias induced by two-stage coronary ligation, digitalis and adrenaline, and compared them with those of mexiletine." | 7.70 | Effects of an antiarrhythmic drug A-2545 on canine ventricular arrhythmia models; comparison with mexiletine and flecainide. ( Arita, J; Aye, NN; Hashimoto, K; Xue, YX, 1998) |
| "Antiarrhythmic effects of bisaramil were examined by using new in vivo triggered arrhythmia models, and they were compared with those of other antiarrhythmic drugs." | 7.69 | Antiarrhythmic effects of bisaramil on triggered arrhythmias produced by intracoronary injection of digitalis and adrenaline in the dog. ( Haruno, A; Hashimoto, K, 1995) |
| "The Cardiac Arrhythmia Suppression Trial has shown that flecainide was associated with an increased incidence of sudden cardiac death in postinfarction patients." | 7.69 | Reentrant arrhythmias in the subacute infarction period. The proarrhythmic effect of flecainide acetate on functional reentrant circuits. ( Assadi, MA; Avitable, MJ; Caref, EB; el-Sherif, N; Isber, N; Ndrepepa, G; Patel, AI; Restivo, M; Yin, H, 1995) |
| "We retrospectively studied the clinical efficacy and safety of oral flecainide in 38 patients with symptomatic arrhythmias." | 7.69 | Safety and efficacy of oral flecainide acetate in patients with cardiac arrhythmias. ( Nakata, Y; Nakazato, K; Nakazato, Y; Ogura, S; Sumiyoshi, M; Yamaguchi, H; Yasuda, M, 1997) |
| "Nine children with arrhythmia (1 automatic atrial tachycardia, 1 premature ventricular construction, and 7 ventricular tachycardia) who started oral treatment using flecainide were studied." | 7.68 | [Effective dose of flecainide for arrhythmia in children]. ( Hara, M; Harada, K; Okuni, M; Otuka, M; Sumitomo, N; Ushinohama, H, 1993) |
| "Because the relative efficacy of antiarrhythmic agents on halothane-epinephrine arrhythmias has not been well characterized, this study was undertaken to comparatively evaluate the antiarrhythmic action of Na(+)-, K(+)- and Ca(2+)-channel blockers on epinephrine-induced ventricular arrhythmias during halothane anesthesia in rats." | 7.68 | Comparative efficacy of antiarrhythmic agents in preventing halothane-epinephrine arrhythmias in rats. ( Hayashi, Y; Kamibayashi, T; Kawabata, K; Sumikawa, K; Takada, K; Yamatodani, A; Yoshiya, I, 1993) |
| "Flecainide (100 mg twice daily) was used for prevention of paroxysmal atrial fibrillation (PAF) in 52 patients with frequent symptomatic attacks that were resistant or intolerant to quinidine (600-900 mg/day)." | 7.68 | Flecainide in quinidine-resistant atrial fibrillation. ( Chouty, F; Coumel, P; Denjoy, I; Leclercq, JF; Slama, R, 1992) |
| "Effects of flecainide, a class I antiarrhythmic drug, on ventricular arrhythmias, ventricular abnormal automaticity and ventricular activation were examined in a canine model of myocardial infarction, and compared with those of lidocaine." | 7.68 | Effects of flecainide on ventricular arrhythmias, abnormal automaticity and activation in a canine model of myocardial infarction. ( Hashimoto, H; Katoh, H; Nakashima, M, 1992) |
| " In this study, we evaluated the effects of adding low dose quinidine, a potent inhibitor of P450IID6, to chronic flecainide therapy in patients with arrhythmias." | 7.68 | Stereoselective genetically-determined interaction between chronic flecainide and quinidine in patients with arrhythmias. ( Birgersdotter, UM; Roden, DM; Turgeon, J; Wong, W, 1992) |
| " The class Ic steroidal antiarrhythmic agent, Org 7797, was compared with two other Ic agents, flecainide and propafenone for intravenous activity against ischaemia-related cardiac arrhythmias and for electrophysiological actions in vivo." | 7.68 | Effects of Org 7797 on early, late and inducible arrhythmias following coronary artery occlusion in rats and dogs. ( Barron, E; Campbell, JK; Marshall, RJ; Muir, AW; Winslow, E, 1991) |
| "In a recent clinical trial, the class Ic antiarrhythmic drugs encainide and flecainide were found to be associated with an increased mortality risk in patients with new myocardial infarction and ventricular arrhythmias." | 7.68 | Mortality in patients treated with flecainide and encainide for supraventricular arrhythmias. ( Pritchett, EL; Wilkinson, WE, 1991) |
| " Programmed electrical stimulation using up to three closely coupled premature stimuli and burst pacing was used to test the inducibility of arrhythmias both during control and administration of 1 micrograms/ml flecainide." | 7.68 | Proarrhythmic effects of flecainide. Experimental evidence for increased susceptibility to reentrant arrhythmias. ( Allessie, M; Boersma, L; Brugada, J; Kirchhof, C, 1991) |
| "The arrhythmogenic effects of flecainide in atrial fibrillation and flutter were assessed in a consecutive material of 100 patients without severe heart failure (NYHA class I or II)." | 7.68 | Flecainide acetate in atrial flutter and fibrillation. The arrhythmogenic effects. ( Hansen, FA; Pedersen, AK; Rasmussen, J; Sihm, I; Thygesen, K, 1990) |
| "To assess the efficacy of encainide and flecainide in treating patients with sustained ventricular arrhythmias." | 7.68 | Inefficacy and proarrhythmic effects of flecainide and encainide for sustained ventricular tachycardia and ventricular fibrillation. ( Eldar, M; Franz, MR; Griffin, JC; Herre, JM; Oeff, M; Scheinman, MM; Titus, C, 1990) |
| " Coadministration of amiodarone, and, moreover, the presence of heart failure increase the C/D ratio, from 2." | 7.68 | Flecainide acetate dose-concentration relationship in cardiac arrhythmias: influence of heart failure and amiodarone. ( Coumel, P; Denjoy, I; Leclercq, JF; Mentré, F, 1990) |
| "During a one-week short-term in-hospital period, 60 patients with chronic ventricular arrhythmias were treated with 200 mg flecainide twice a day." | 7.67 | Flecainide: one-year efficacy in patients with chronic ventricular arrhythmias. ( Balakumaran, K; Hagemeijer, F; Hugenholtz, PG; Jovanovic, A; Lubsen, J; Polak, BC; Roelandt, J; ten Cate, FJ; Vanhaleweyk, G; Withagen, A, 1984) |
| "Flecainide acetate was evaluated in a placebo-controlled, dose-ranging study performed in patients with stable, high-frequency ventricular arrhythmias." | 7.67 | Flecainide dose-response relations in stable ventricular arrhythmias. ( Duff, HJ; Roden, DM; Siddoway, LA; Woosley, RL, 1984) |
| "The efficacy and safety of oral flecainide for treatment of ventricular arrhythmias were assessed during a 3-day period in patients with various cardiac diseases." | 7.67 | Oral flecainide for suppression of ventricular arrhythmias. ( Balakumaran, K; Hugenholtz, PG; Lubsen, J; Roelandt, J; Vanhaleweyk, G, 1984) |
| "The long-term efficacy and safety of flecainide (100 to 200 mg twice a day) were evaluated in 21 patients with high-grade, chronic ventricular arrhythmias who responded to and tolerated flecainide at a preliminary evaluation (200 mg, single oral dose)." | 7.67 | Efficacy and safety of flecainide in low-risk patients with chronic ventricular arrhythmias: a two-year follow-up. ( Bonazzi, O; Facchini, M; Priori, SG; Schwartz, PJ; Songa, V; Varisco, T, 1989) |
| "Drug efficacy and pharmacokinetics were assessed in 63 patients, aged 5 days to 30 years (mean 8 years), who received flecainide acetate for control of resistant arrhythmias." | 7.67 | Flecainide acetate for resistant arrhythmias in the young: efficacy and pharmacokinetics. ( Fredell, P; Garson, A; Gothing, C; McQuinn, RL; Perry, JC; Smith, RT, 1989) |
| "The properties of a class 1c antiarrhythmic drug, flecainide, were examined using 3 canine ventricular arrhythmia models: (1) digitalis-, (2) adrenaline- and (3) two-stage coronary ligation-induced arrhythmias." | 7.67 | Antiarrhythmic effects of the class 1c antiarrhythmic drug, flecainide, on canine ventricular arrhythmia models. ( Akiyama, K; Hashimoto, K, 1989) |
| "Flecainide has been reported to be effective in suppressing chronic ventricular arrhythmias in clinical studies, but the electrophysiological mechanisms of its action are not understood." | 7.67 | Electrophysiological effects of flecainide in a canine 7 day old myocardial infarction model. ( Hosokawa, M; Miyazaki, T; Nakamura, Y; Ogawa, S; Sakai, T; Sakurai, K, 1989) |
| "A 65 year old man with recurrent ventricular tachyarrhythmias post myocardial infarction developed dysarthria and visual hallucinations due to flecainide toxicity." | 7.67 | Dysarthria and visual hallucinations due to flecainide toxicity. ( Mackenzie, S; Ramhamadany, E; Ramsdale, DR, 1986) |
| "Thirty-nine patients with symptomatic ectopic atrial tachycardia (9 paroxysmal, of which 5 were incessant) and atrial fibrillation (AF) (25 paroxysmal, 5 chronic) were treated with oral flecainide acetate (100 to 400 mg/day)." | 7.67 | Efficacy and safety of flecainide acetate for atrial tachycardia or fibrillation. ( Berns, E; Dougherty, AH; Jeang, MK; Jenkins, M; Naccarelli, GV; Rinkenberger, RL, 1987) |
| "Plasma flecainide concentrations were measured in 10 patients with acute myocardial infarction." | 7.67 | Plasma flecainide concentrations following acute myocardial infarction. ( Bhamra, R; Holt, DW; Jackson, G; Johnston, A; Ong, ML, 1987) |
| "Oral flecainide was administered to 98 patients with arrhythmias regarded as resistant to other antiarrhythmic agents: quinidines (82), propafenone (40), beta-blockers (30), amiodarone alone (38) or combined with a class I compound (19)." | 7.67 | [Oral flecainide in the treatment of refractory arrhythmias. Long-term follow-up of 98 patients]. ( Benchimol, D; Blanchot, P; Haissaguerre, M; Le Métayer, P; Regaudie, JJ; Warin, JF, 1987) |
| "A two-part pharmacokinetic approach was used to prospectively develop and test intravenous flecainide infusion regimens for the acute therapy for ventricular arrhythmias." | 7.67 | The development and testing of intravenous dosing regimens: application to flecainide for the suppression of ventricular arrhythmias. ( Bergstrand, RH; Conard, GJ; Kvam, D; Roden, DM; Siddoway, LA; Thompson, KA; Wang, T; Woosley, RL, 1988) |
| "We treated 22 children, aged 3 days to 16 years 6 months (median 11 years 1 month), with flecainide for a variety of arrhythmias where a Class I agent was indicated." | 7.67 | Experience with flecainide for the treatment of cardiac arrhythmias in children. ( Curry, PV; Holt, DW; Jones, OD; Ladusans, EJ; Priestley, KA; Rosenthal, E; Tynan, MJ, 1988) |
| "The effect of flecainide in 24 patients with inducible sustained ventricular arrhythmia and a history of remote myocardial infarction was determined." | 7.67 | Flecainide: steady state electrophysiologic effects in patients with remote myocardial infarction and inducible sustained ventricular arrhythmia. ( Greenspan, AM; Horowitz, LN; Morganroth, J; Senior, S; Spielman, SR; Webb, CR, 1986) |
| "Ninety-four patients with ventricular tachycardia (VT), 49 with sustained and 45 with nonsustained VT, who had been refractory to or intolerant of other antiarrhythmic agents were treated in a multicenter, open-label study with flecainide acetate." | 7.67 | Treatment of resistant ventricular tachycardia with flecainide acetate. Flecainide Ventricular Tachycardia Study Group. ( , 1986) |
| " This study assessed in 1,330 patients followed up for 292 +/- 393 days the predictive value for cardiovascular safety of a system by which patients were classified according to ventricular arrhythmias on entry, presence or absence of organic heart disease and drug dose for flecainide acetate." | 7.67 | Classification by type of ventricular arrhythmia predicts frequency of adverse cardiac events from flecainide. ( Anderson, JL; Gentzkow, GD; Morganroth, J, 1986) |
| "The objective of this study was to evaluate the haemodynamic and antiarrhythmic effects of flecainide acetate in patients with heart failure." | 7.67 | Haemodynamic and antiarrhythmic effects of intravenous flecainide acetate in chronic congestive heart failure. ( Dijk, A; Dunselman, PH; Kingma, JH; Lie, KI; van Wijk, LM; Wesseling, H, 1985) |
| "The efficacy of the new class Ic anti-arrhythmic (aa) drug, Flecainide, has been evaluated in patients (pts) affected by frequent and/or severe chronic ventricular arrhythmias (VA), as assessed by 24 hours Holter monitoring and maximal exercise stress testing." | 7.67 | [Evaluation of flecainide in the therapy of chronic ventricular arrhythmia using the acute oral load method]. ( Bonazzi, O; Cuspidi, C; Facchini, M; Priori, S; Schwartz, PJ; Varisco, T; Zuanetti, G, 1985) |
| "After an initial pilot study in five patients, the effect of flecainide on chronic ventricular arrhythmias was tested during 48-hour oral administration of 250 mg twice a day in nine further patients with previously drug-resistant chronic, stable ventricular arrhythmias." | 7.66 | [Effect of flecainide on chronic ventricular arrhythmias (author's transl)]. ( Abendroth, RR; Bluschke, V; Breithardt, G; Seipel, L, 1982) |
| " At the dosage used side effects related to flecainide or digoxin were not observed." | 6.67 | Prevention of arrhythmias after noncardiac thoracic operations: flecainide versus digoxin. ( Biollaz, J; Borgeat, A; Cavin, R; Munafo, A; Petropoulos, P; Schwander, D, 1991) |
| "Cardiac arrhythmias are a frequent complication after thoracic operations." | 6.66 | Prevention of arrhythmias by flecainide after noncardiac thoracic surgery. ( Bayer-Berger, M; Biollaz, J; Borgeat, A; Chapuis, G; Chioléro, R; Kappenberger, L, 1989) |
| " During a double-blind drug and dose selection phase, investigators were permitted to change drug or dosage to achieve greater than or equal to 70% suppression in VPC frequency and greater than 90% suppression of runs of VPC with the exception of patients assigned to placebo, who continued receiving it." | 6.66 | Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: the CAPS. ( , 1988) |
| "Flecainide was as effective as the combination of digoxin and disopyramide and it acted significantly faster and was associated with fewer relapses." | 6.66 | Flecainide compared with a combination of digoxin and disopyramide for acute atrial arrhythmias after cardiopulmonary bypass. ( Campbell, TJ; Gavaghan, TP; Kelly, RP; Koegh, AM; Morgan, JJ; Thorburn, C, 1988) |
| "Flecainide was more effective than quinidine in suppressing chronic ventricular arrhythmias (especially complex forms), and thus is an important new antiarrhythmic agent." | 6.65 | Flecainide versus quinidine for treatment of chronic ventricular arrhythmias. A multicenter clinical trial. ( , 1983) |
| "Flecainide was injected intravenously at a rate of 20 mg per 2 min until complete disappearance of ventricular arrhythmias or up to a total dose not exceeding 200 mg." | 6.65 | Efficacy and tolerance of intravenous flecainide in patients with chronic high frequency ventricular arrhythmias. ( Andries, E; Kesteloot, H; Stroobandt, R; van Mieghem, W, 1984) |
| "Flecainide thus appears to be a highly effective and well-tolerated antiarrhythmic agent with favorable pharmacokinetics." | 6.65 | Oral flecainide acetate for the treatment of ventricular arrhythmias. ( Anderson, JL; Chang, SF; Conard, GJ; Johnson, TA; Kvam, DC; Perry, BA; Pitt, B; Stewart, JR; Van Hamersveld, DD, 1981) |
| " Flecainide appeared to be safe (no deaths with usual oral dosing, < 1% serious proarrhythmia) and effective (73% to 100% control, depending on mechanism) in children with supraventricular tachycardia." | 6.38 | Flecainide acetate for treatment of tachyarrhythmias in children: review of world literature on efficacy, safety, and dosing. ( Garson, A; Perry, JC, 1992) |
| "These arrhythmias are divided in 31 atrial fibrillation, 11 tachy-systoles, 18 atrial flutters." | 6.38 | [Comparative study of cibenzoline and flecainide administered via an intravenous route in reducing auricular arrhythmia]. ( Bajolet, A; Chabert, JP; Chapoutot, L; Ehrhard, V; Laudinat, JM; Metivet, F; Metz, D; Pollet, E; Taupin, JM, 1990) |
| "Flecainide has been shown to be a relatively safe and effective antiarrhythmic agent." | 6.37 | Flecainide: a new agent for the treatment of ventricular arrhythmias. ( Grubb, BP; Tilley-Gray, B, 1986) |
| "Flecainide and propafenone are antiarrhythmic drugs of the class 1C (Vaughan and Williams) commonly used for ventricular arrhythmias." | 6.17 | [Propafenone and flecainide in the therapy of ventricular arrhythmias]. ( Davini, A; Lattanzi, F; Paci, A; Paperini, L; Reisenhofer, B; Squarcini, G; Topi, A; Topi, PL, 1995) |
| " Furthermore, the Cardiac Arrhythmia Pilot Study compared moricizine in postinfarction patients with encainide and flecainide." | 6.16 | Comparisons of efficacy and tolerance of moricizine with other antiarrhythmic agents in the treatment of chronic ventricular arrhythmias. ( Anderson, JL, 1990) |
| "Flecainide was found to prolong ventricular repolarization, with effect being greater at the left ventricular compared with the right ventricular epicardium." | 5.38 | Flecainide-induced proarrhythmia is attributed to abnormal changes in repolarization and refractoriness in perfused guinea-pig heart. ( Osadchii, OE, 2012) |
| "Phase-2 ventricular arrhythmias occur during infarct evolution." | 5.33 | Actions of flecainide on susceptibility to phase-2 ventricular arrhythmias during infarct evolution in rat isolated perfused hearts. ( Clements-Jewery, H; Curtis, MJ; Kabra, R; Kanaganayagam, GS, 2006) |
| "Flecainide was found to induce extrasystolic activity more readily than other sodium blockers." | 5.29 | Flecainide-induced arrhythmia in canine ventricular epicardium. Phase 2 reentry? ( Antzelevitch, C; Krishnan, SC, 1993) |
| "Oral flecainide treatment was given to five patients who were refractory to conventional antiarrhythmic agents." | 5.28 | [Effects of oral flecainide treatment of refractory tachyarrhythmias]. ( Hiraoka, M; Hiyoshi, Y; Motomiya, T; Sakurada, H; Sugiura, M; Tejima, T; Tokuyasu, Y; Watanabe, K; Yanase, O, 1990) |
| " The administration of flecainide, dosage 1." | 5.28 | [A case of atrial paralysis during the use of intravenous flecainide acetate]. ( Pardini, E; Tognarini, S, 1989) |
| "For single ventricular extrasystoles, doublets and triplets, nine very good results (80 to 100 per cent reduction of arrhythmia) and four 50 to 80 per cent reductions in ventricular prematurity were obtained." | 5.27 | [Study of flecainide in the treatment of ventricular arrhythmia]. ( Errera, J; Hug, C; Koliopoulos, N; Puech, P; Tardy, C, 1983) |
| "Flecainide appears to be an effective agent for the conversion to sinus rhythm of atrial fibrillation and supraventricular tachycardias." | 5.27 | Conversion of supraventricular arrhythmias to sinus rhythm using flecainide. ( Duc, J; Finci, L; Goy, JJ; Grbic, M; Hurni, M; Maendly, R; Sigwart, U, 1985) |
| "Six patients with short QT syndrome, five of whom had received an implantable cardioverter-defibrillator (ICD) and one child, were tested with different antiarrhythmic drugs, including flecainide, sotalol, ibutilide, and hydroquinidine, to determine whether they could prolong the QT interval into the normal range and thus prevent symptoms and arrhythmia recurrences." | 5.11 | Short QT syndrome: pharmacological treatment. ( Antzelevitch, C; Bianchi, F; Borggrefe, M; Brugada, R; Calò, L; Gaita, F; Giustetto, C; Haissaguerre, M; Schimpf, R; Wolpert, C, 2004) |
| "In this study we investigated the time to the first arrhythmic, ischemic, or failure event for encainide-flecainide and moricizine versus their respective placebo comparison groups in the Cardiac Arrhythmia Suppression Trial." | 5.08 | Time to arrhythmic, ischemic, and heart failure events: exploratory analyses to elucidate mechanisms of adverse drug effects in the Cardiac Arrhythmia Suppression Trial. ( Anderson, JL; Carlson, M; Davies, R; Duff, HJ; Greene, HL; Hallstrom, AP; Huther, M; Kammerling, JM; Romhilt, DW, 1995) |
| "Patients with supraventricular arrhythmias have been safely and effectively treated with flecainide." | 5.08 | Safety and utility of flecainide acetate in the routine care of patients with supraventricular tachyarrhythmias: results of a multicenter trial. The Flecainide Supraventricular Tachycardia Study Group. ( Buxton, AE; Heilman, JM; Hopson, JR; Kienzle, MG; Nademanee, K; Rinkenberger, RL, 1996) |
| "In order to compare the long-term safety of flecainide and propafenone, an open label, randomized, parallel group study was performed in 335 patients with paroxysmal atrial fibrillation (n = 200) or paroxysmal supraventricular tachycardia (n = 135), and no history of heart disease." | 5.08 | Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group. ( Casadei, G; Chimienti, M; Cullen, MT, 1995) |
| " The Cardiac Arrhythmia Suppression Trial (CAST), a placebo-controlled double-blind clinical trial of post-myocardial infarction (MI) patients with asymptomatic ventricular arrhythmias, in which active medication (encainide or flecainide) led to increased mortality, provided an opportunity to examine the relationship of adherence to survival from a different perspective." | 5.08 | Adherence and arrhythmic mortality in the cardiac arrhythmia suppression trial (CAST). ( Brooks, MM; Friedmann, E; Goldner, F; Haakenson, C; Morris, M; Obias-Manno, D; Somelofski, C; Thomas, SA; Wimbush, F, 1996) |
| "Although active treatment in CAST-I was associated with greater mortality than placebo with respect to almost all baseline variables, the therapeutic hazard was more than expected in patients with non-Q-wave myocardial infarction and (for total mortality) frequent premature VPDs and higher heart rates, suggesting that the adverse effect of encainide or flecainide therapy is greater when ischemic and electrical instability are present." | 5.07 | Interaction of baseline characteristics with the hazard of encainide, flecainide, and moricizine therapy in patients with myocardial infarction. A possible explanation for increased mortality in the Cardiac Arrhythmia Suppression Trial (CAST). ( Anderson, JL; Buckingham, TA; Carlson, MD; Carson, PE; Hallstrom, A; Henthorn, RW; Platia, EV, 1994) |
| "Evaluation of efficacy of intravenous flecainide to revert supraventricular arrhythmias to sinus rhythm in patients with respiratory insufficiency." | 5.07 | Efficacy of flecainide in patients with supraventricular arrhythmias and respiratory insufficiency. ( Barranco, F; Guerrero, M; Rodriguez, J; Sanchez, M, 1994) |
| "The Cardiac Arrhythmia Suppression Trial (CAST) was a multicenter double-blind, placebo-controlled study designed to determine whether suppression of ventricular ectopic activity by means of antiarrhythmic drugs (encainide, flecainide or moricizine) after acute myocardial infarction would reduce the incidence of arrhythmic death." | 5.07 | Circadian pattern of arrhythmic death in patients receiving encainide, flecainide or moricizine in the Cardiac Arrhythmia Suppression Trial (CAST). ( Barker, AH; Brooks, MM; Capone, R; Echt, DS; Greene, HL; Liebson, PR; Mitchell, LB; Peters, RW, 1994) |
| "The efficacy and safety of intravenous flecainide to convert recent-onset atrial fibrillation (AF) (present for greater than or equal to 30 minutes and less than or equal to 72 hours and a ventricular response greater than or equal to 120 beats/min) was investigated." | 5.07 | Efficacy of flecainide for the reversion of acute onset atrial fibrillation. ( Clarke, GM; Coombs, LJ; Dobb, GJ; Donovan, KD; Lee, KY; Murdock, CJ; Weekes, JN, 1992) |
| "The pharmacokinetics of flecainide has been studied in 12 patients with ventricular arrhythmias, both after single administration and during chronic treatment." | 5.07 | Flecainide: evidence of non-linear kinetics. ( Ambrosioni, E; Boriani, G; Callivà, R; Capucci, A; Frabetti, L; Magnani, B; Strocchi, E, 1991) |
| "In the Cardiac Arrhythmia Suppression Trial, designed to test the hypothesis that suppression of ventricular ectopy after a myocardial infarction reduces the incidence of sudden death, patients in whom ventricular ectopy could be suppressed with encainide, flecainide, or moricizine were randomly assigned to receive either active drug or placebo." | 5.07 | Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. ( Arensberg, D; Baker, A; Barker, AH; Echt, DS; Friedman, L; Greene, HL; Liebson, PR; Mitchell, LB; Obias-Manno, D; Peters, RW, 1991) |
| "Patients randomized to placebo in the encainide and flecainide arms of the Cardiac Arrhythmia Suppression Trial (CAST) have been found to have a relatively low 1-year mortality rate of 3." | 5.07 | Events in the cardiac arrhythmia suppression trial: baseline predictors of mortality in placebo-treated patients. ( Capone, RJ; el-Sherif, N; Geraci, TS; Handshaw, K; Morganroth, J; Pawitan, Y; Schlant, RC; Waldo, AL, 1991) |
| "Moricizine was studied in 908 patients with ventricular arrhythmias." | 5.06 | Proarrhythmic potential of moricizine: strengths and limitations of a data base analysis. ( Pratt, CM, 1990) |
| "The best therapeutic approach to the therapy of potentially malignant ventricular arrhythmias is still unknown, particularly in view of the increased mortality with flecainide and encainide shown in the CAST study." | 5.06 | Recasting the approach to the treatment of potentially malignant ventricular arrhythmias after the CAST study. ( Bayés de Luna, A; Borja, J; Guindo, J; Madoery, C; Roman, M, 1990) |
| " The Cardiac Arrhythmia Suppression Trial (CAST) is evaluating the effect of antiarrhythmic therapy (encainide, flecainide, or moricizine) in patients with asymptomatic or mildly symptomatic ventricular arrhythmia (six or more ventricular premature beats per hour) after myocardial infarction." | 5.06 | Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. ( , 1989) |
| "The antiarrhythmic efficacy of intravenous flecainide and intravenous digoxin was assessed in 29 patients (26 men), aged 43 to 73 (63 +/- 7) years who developed atrial arrhythmias in the first 96 hours after coronary artery bypass grafting." | 5.06 | Efficacy of flecainide acetate for atrial arrhythmias following coronary artery bypass grafting. ( Camm, AJ; Parker, DJ; Wafa, SS; Ward, DE, 1989) |
| "Encainide and flecainide are two recently released class IC antiarrhythmic agents that have been reported to be highly effective for suppressing all forms of ventricular arrhythmias." | 5.06 | Encainide and flecainide: are they interchangeable? ( Lown, B; Podrid, PJ; Saini, V; Slater, W, 1989) |
| "The aim of this multicentre study, carried out by the Italian Study Group on the Electrophysiology of Arrhythmias (GISEA) in 60 Italian Cardiology Centres on 260 patients, was to assess the efficacy and the safety of flecainide in the treatment of stable hyperkinetic ventricular arrhythmias (greater than 100 ventricular ectopic beats/hour per day)." | 5.06 | Efficacy and safety of flecainide in patients with stable ventricular ectopic beats. Multicenter trial of the Italian Study Group on the Electrophysiology of Arrhythmias. ( , 1989) |
| "The efficacy and safety of flecainide were studied in the maintenance of sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter." | 5.06 | Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter. ( Crijns, HJ; Hamer, HP; Lie, KI; Van Gelder, IC; Van Gilst, WH; Van Wijk, LM, 1989) |
| "Flecainide, a new antiarrhythmic drug (group 1 according to the classification after Vaughan Williams), is used in the treatment of atrial and ventricular arrhythmias." | 5.06 | [Hemodynamic effects of the anti-arrhythmia agent flecainide (Tambocor) in coronary surgery patients]. ( Boldt, J; Görlach, G; Hempelmann, G; Kling, D; Russ, W, 1987) |
| "The effectiveness and safety of oral flecainide for suppression of complex ventricular arrhythmias was tested in nine patients in a short-term (4 wk), single-blind, placebo-controlled experiment." | 5.05 | Suppression of complex ventricular arrhythmias by oral flecainide. ( Adhar, G; Duran, D; Griffith, LS; Platia, EV; Reid, PR, 1982) |
| "The effects on ventricular arrhythmias of a new class IA drug, flecainide, were compared with those of amiodarone in 10 patients with frequent, chronic, and stable ventricular ectopic beats (VEBs)." | 5.05 | Efficacy of flecainide in the management of ventricular arrhythmias: comparative study with amiodarone. ( Bertolasi, CA; Dubner, SJ; Elencwajg, BD; Mendelzon, R; Palma, S; Ramos, A, 1985) |
| "The aim of this review is to evaluate the available data on efficacy and safety of flecainide in all the spectrum of its indications including cardioversion of recent-onset AF, sinus rhythm maintenance in paroxysmal AF and management of ventricular tachyarrhythmias." | 4.89 | Flecainide acetate for the treatment of atrial and ventricular arrhythmias. ( Apostolakis, S; Breithardt, G; Fabritz, L; Kirchhof, P; Oeff, M; Tebbe, U, 2013) |
| "Flecainide (CAS 54143-55-4) has been associated with increased mortality in patients with ventricular dysfunction and arrhythmias." | 4.81 | Meta-analysis of flecainide safety in patients with supraventricular arrhythmias. ( Wehling, M, 2002) |
| "A variety of recent in vivo studies have sought to clarify the mechanism underlying the proarrhythmic response of flecainide in the Cardiac Arrhythmia Suppression Trial (CAST)." | 4.79 | Mechanism of lethal proarrhythmia observed in the Cardiac Arrhythmia Suppression Trial: role of adrenergic modulation of drug binding. ( Cragun, KT; Johnson, SB; Munger, TM; Packer, DL, 1997) |
| "This report summarizes efficacy and safety data on the use of flecainide acetate for supraventricular arrhythmias." | 4.78 | Short- and long-term efficacy and safety of flecainide acetate for supraventricular arrhythmias. ( Hohnloser, SH; Zabel, M, 1992) |
| "The effects of flecainide on electrophysiologic parameters and arrhythmias in the Wolff-Parkinson-White syndrome were reviewed." | 4.78 | Flecainide in the Wolff-Parkinson-White syndrome. ( Crozier, I, 1992) |
| "Flecainide may play an important role in the treatment of ventricular arrhythmias because of its convenient dosing regimen and high rate of efficacy in controlling ventricular ectopic activity." | 4.77 | Flecainide acetate: critical care administration guidelines. ( Baessler, C; Monzo, M; Senior, S, 1988) |
| "Flecainide is a benzenacetamide synthesised about a decade ago and only recently introduced into the treatment of arrhythmias." | 4.77 | [Flecainide and anti-arrhythmia therapy]. ( Croce, L; Lomuscio, A; Pozzoni, L; Romano, S, 1988) |
| "Flecainide is a class 1C antiarrhythmic and is highly effective for treating a wide range of arrhythmias." | 4.31 | Flecainide toxicity: ECG changes associated with supratherapeutic levels in milk-fed infants. ( Bellsham-Revell, H; Bhatt, H; Regan, W; Rosenthal, E, 2023) |
| " Treatment with flecainide and propranolol achieved successful control of the incessant arrhythmia with improvement in cardiac function on echocardiogram." | 4.31 | Wide complex rhythm in a well neonate: Where are the P waves? ( Jee, G; Ofoe, V; Uzun, O; Wong, A, 2023) |
| "High-dose flecainide and digoxin combination offers effective treatment strategy in fetuses with hydrops and tachyarrhythmia with favourable outcomes." | 4.12 | Favourable outcome for hydrops or cardiac failure associated with fetal tachyarrhythmia: a 20-year review. ( Beattie, RB; Tunca Sahin, G; Uzun, O, 2022) |
| "Sotalol and flecainide are used as second line agents in children for the treatment of supraventricular arrhythmias (SA) refractory to anti-beta adrenergic antiarrhythmics or digoxin." | 4.02 | "Second line medications" for supraventricular arrhythmias in children: In-hospital efficacy and adverse events during treatment initiation of sotalol and flecainide. ( Kahr, PC; Kim, JJ; Miyake, CY; Moffett, BS; Valdes, SO, 2021) |
| "Flecainide-induced arrhythmia may be partly accounted for by attenuated adaptation of ventricular repolarization to sudden changes in cardiac cycle length provoked by transient tachycardia or ectopic beats." | 3.83 | Flecainide attenuates rate adaptation of ventricular repolarization in guinea-pig heart. ( Osadchii, OE, 2016) |
| "Antiarrhythmic agents which belong to class Ia (quinidine) and Ic (flecainide) reportedly increase propensity to ventricular tachyarrhythmia, whereas class Ib agents (lidocaine and mexiletine) are recognized as safe antiarrhythmics." | 3.80 | Effects of Na+ channel blockers on extrasystolic stimulation-evoked changes in ventricular conduction and repolarization. ( Osadchii, OE, 2014) |
| "Although flecainide has a risk of proarrhythmia in patients with structural heart disease, its mechanism has been mainly ascribed to use-dependency and a rapid ventricular response to organized atrial tachyarrhythmias or to ventricular tachycardia." | 3.79 | Flecainide-associated bradycardia-dependent torsade de pointes: another potential mechanism of proarrhythmia. ( Kim, HS; Kim, SS; Pak, HN; Park, JS, 2013) |
| "Thirty-three patients received flecainide because of exercise-induced ventricular arrhythmias despite conventional (for different reasons, not always optimal) therapy (median age 25 years; range 7 to 68 years; 73% female)." | 3.77 | Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. ( Bhuiyan, ZA; Fish, FA; Haïssaguerre, M; Kannankeril, PJ; Knollmann, BC; Krahn, AD; Laborderie, J; Leenhardt, A; Sacher, F; Shimizu, W; Sumitomo, N; van der Veen, MJ; van der Werf, C; Viskin, S; Watanabe, H; Wilde, AA; Willems, AR, 2011) |
| "To assess the safety of long-term treatment with flecainide in patients with atrial fibrillation (AF), particularly with regard to sudden cardiac death (SCD) and proarrhythmic events." | 3.77 | The safety of flecainide treatment of atrial fibrillation: long-term incidence of sudden cardiac death and proarrhythmic events. ( Almroth, H; Andersson, T; Englund, A; Fengsrud, E; Friberg, L; Linde, P; Rosenqvist, M, 2011) |
| "The Cardiac Arrhythmia Suppression Trial (CAST) was designed to test the hypothesis that suppression of ventricular premature complexes (VPCs) in survivors of acute myocardial infarction would reduce arrhythmic death risk." | 3.76 | The Cardiac Arrhythmia Suppression Trial: background, interim results and implications. ( Moye, LA; Pratt, CM, 1990) |
| "Flecainide acetate is a new orally active antidysrhythmic agent classified in the Ic category." | 3.75 | Flecainide: a new class Ic antidysrhythmic. ( Smith, GH, 1985) |
| "We designed the present study to examine whether diabetes mellitus affects the antiarrhythmic effect of flecainide, a sodium channel blocker, E-4031, a potassium channel blocker, and verapamil, a calcium channel blocker, in diabetic rats." | 3.73 | Diabetes mellitus reduces the antiarrhythmic effect of ion channel blockers. ( Hayashi, Y; Ito, I; Iwasaki, M; Kamibayashi, T; Kawai, Y; Mashimo, T; Takada, K; Yamatodani, A, 2006) |
| "Cardiac arrhythmias are frequent by hemodialyzed patients and may lead to the prescription of antiarrhythmic drugs among which flecainide." | 3.73 | [Be careful in using flecainide by hemodialyzed patients]. ( Aliouche, CP; Montagnac, R; Schillinger, F; Schoen, E, 2006) |
| " flecainide has a high efficacy for the treatment of experimentally-induced acute atrial fibrillation (AF) in horses and that its use is associated with minimal toxic side effects." | 3.72 | Use of intravenous flecainide in horses with naturally-occurring atrial fibrillation. ( Blissitt, KJ; Keen, JA; van Loon, G; Young, LE, 2004) |
| " Pilsicainide (four patients) or flecainide (one patient) were administered orally for the treatment of symptomatic paroxysmal atrial fibrillation or premature atrial contractions." | 3.71 | ST segment elevation in the right precordial leads following administration of class Ic antiarrhythmic drugs. ( Kawano, Y; Mineda, Y; Nakata, Y; Nakazato, K; Nakazato, Y; Sekita, G; Sumiyoshi, M; Tokano, T; Yamashita, H; Yasuda, M, 2001) |
| "We have linked 2 inactivation gating defects ("closed-state" fast inactivation and intermediate inactivation) to flecainide sensitivity in patients carrying LQT3 and Brugada syndrome mutations." | 3.71 | Gating-dependent mechanisms for flecainide action in SCN5A-linked arrhythmia syndromes. ( Balser, JR; Bezzina, CR; George, AL; Roden, DM; Viswanathan, PC; Wilde, AA, 2001) |
| "We investigated effects of a new Na+ channel blocking antiarrhythmic drug, A-2545, N-3 (2,2,5,5-tetramethyl-3-pyrroline-3-carboxamido)-propyl-phthalimide-hydro chloride, on various canine ventricular automaticity arrhythmias induced by two-stage coronary ligation, digitalis and adrenaline, and compared them with those of mexiletine." | 3.70 | Effects of an antiarrhythmic drug A-2545 on canine ventricular arrhythmia models; comparison with mexiletine and flecainide. ( Arita, J; Aye, NN; Hashimoto, K; Xue, YX, 1998) |
| "Antiarrhythmic effects of bisaramil were examined by using new in vivo triggered arrhythmia models, and they were compared with those of other antiarrhythmic drugs." | 3.69 | Antiarrhythmic effects of bisaramil on triggered arrhythmias produced by intracoronary injection of digitalis and adrenaline in the dog. ( Haruno, A; Hashimoto, K, 1995) |
| "In clinical studies, flecainide, a class IC antiarrhythmic drug, exhibited antiarrhythmic properties against supraventricular arrhythmias but also showed proarrhythmic effects in ventricular arrhythmias." | 3.69 | Use- and concentration-dependent effects of flecainide in guinea pig right ventricular muscle. ( Ducouret, P; Rouet, R, 1994) |
| "The class IC antiarrhythmic drug flecainide has been shown to be ineffective for the treatment of ventricular arrhythmias in some patients who have had a prior myocardial infarction and sometimes even provoke arrhythmias (proarrhythmic effect)." | 3.69 | Electrophysiological effects of flecainide on anisotropic conduction and reentry in infarcted canine hearts. ( Coromilas, J; Dillon, SM; Saltman, AE; Waldecker, B; Wit, AL, 1995) |
| "The Cardiac Arrhythmia Suppression Trial has shown that flecainide was associated with an increased incidence of sudden cardiac death in postinfarction patients." | 3.69 | Reentrant arrhythmias in the subacute infarction period. The proarrhythmic effect of flecainide acetate on functional reentrant circuits. ( Assadi, MA; Avitable, MJ; Caref, EB; el-Sherif, N; Isber, N; Ndrepepa, G; Patel, AI; Restivo, M; Yin, H, 1995) |
| "Flecainide may increase the incidence of cardiac arrhythmias in acute ischemia." | 3.69 | Proarrhythmic actions of flecainide in an isolated tissue model of ischemia and reperfusion. ( Ferrier, GR; Heisler, BE, 1996) |
| "Flecainide was associated with excess mortality distributed virtually equally throughout the period of the Cardiac Arrhythmia Suppression Trial, suggesting the intersection of two events, drug effect and perhaps ischemia." | 3.69 | Flecainide and the electrophysiologic matrix: the effects of flecainide acetate on the determinants of cardiac excitability in sheep Purkinje fibers. ( Arnsdorf, MF; Sawicki, GJ, 1996) |
| "We retrospectively studied the clinical efficacy and safety of oral flecainide in 38 patients with symptomatic arrhythmias." | 3.69 | Safety and efficacy of oral flecainide acetate in patients with cardiac arrhythmias. ( Nakata, Y; Nakazato, K; Nakazato, Y; Ogura, S; Sumiyoshi, M; Yamaguchi, H; Yasuda, M, 1997) |
| " Initial assessment of class I efficacy was carried out in a ouabain-induced arrhythmia model in guinea pigs." | 3.68 | Synthesis and cardiac electrophysiological activity of aryl-substituted derivatives of the class III antiarrhythmic agent sematilide. Potential class I/III agents. ( Argentieri, TM; Gomez, RP; Lind, JM; Morgan, TK; Nickisch, K; Phillips, GB; Sullivan, ME; Wohl, RA, 1990) |
| "Nine children with arrhythmia (1 automatic atrial tachycardia, 1 premature ventricular construction, and 7 ventricular tachycardia) who started oral treatment using flecainide were studied." | 3.68 | [Effective dose of flecainide for arrhythmia in children]. ( Hara, M; Harada, K; Okuni, M; Otuka, M; Sumitomo, N; Ushinohama, H, 1993) |
| "Because the relative efficacy of antiarrhythmic agents on halothane-epinephrine arrhythmias has not been well characterized, this study was undertaken to comparatively evaluate the antiarrhythmic action of Na(+)-, K(+)- and Ca(2+)-channel blockers on epinephrine-induced ventricular arrhythmias during halothane anesthesia in rats." | 3.68 | Comparative efficacy of antiarrhythmic agents in preventing halothane-epinephrine arrhythmias in rats. ( Hayashi, Y; Kamibayashi, T; Kawabata, K; Sumikawa, K; Takada, K; Yamatodani, A; Yoshiya, I, 1993) |
| "Flecainide (100 mg twice daily) was used for prevention of paroxysmal atrial fibrillation (PAF) in 52 patients with frequent symptomatic attacks that were resistant or intolerant to quinidine (600-900 mg/day)." | 3.68 | Flecainide in quinidine-resistant atrial fibrillation. ( Chouty, F; Coumel, P; Denjoy, I; Leclercq, JF; Slama, R, 1992) |
| "Effects of flecainide, a class I antiarrhythmic drug, on ventricular arrhythmias, ventricular abnormal automaticity and ventricular activation were examined in a canine model of myocardial infarction, and compared with those of lidocaine." | 3.68 | Effects of flecainide on ventricular arrhythmias, abnormal automaticity and activation in a canine model of myocardial infarction. ( Hashimoto, H; Katoh, H; Nakashima, M, 1992) |
| " In this study, we evaluated the effects of adding low dose quinidine, a potent inhibitor of P450IID6, to chronic flecainide therapy in patients with arrhythmias." | 3.68 | Stereoselective genetically-determined interaction between chronic flecainide and quinidine in patients with arrhythmias. ( Birgersdotter, UM; Roden, DM; Turgeon, J; Wong, W, 1992) |
| " RS-2135 exerted more potent antiarrhythmic activity than reference compounds against ouabain-induced arrhythmias in dogs." | 3.68 | Antiarrhythmic and cardiovascular profiles of the fused indole compound (3aR,12R,12aR,12bS)-12-amino-2,3,3a,4,11,12,12a,12b-octahydro-10-hydrox yisoquino [2,1,8-lma]carbazol-5(1H)-one hydrochloride 1.5 hydrate. ( Fukami, M; Hashimoto, T; Itoh, Y; Koike, H; Kumakura, S; Miyake, S; Mizuno, H; Shiga, H; Shimoji, Y; Yorikane, R, 1991) |
| " The class Ic steroidal antiarrhythmic agent, Org 7797, was compared with two other Ic agents, flecainide and propafenone for intravenous activity against ischaemia-related cardiac arrhythmias and for electrophysiological actions in vivo." | 3.68 | Effects of Org 7797 on early, late and inducible arrhythmias following coronary artery occlusion in rats and dogs. ( Barron, E; Campbell, JK; Marshall, RJ; Muir, AW; Winslow, E, 1991) |
| "In a recent clinical trial, the class Ic antiarrhythmic drugs encainide and flecainide were found to be associated with an increased mortality risk in patients with new myocardial infarction and ventricular arrhythmias." | 3.68 | Mortality in patients treated with flecainide and encainide for supraventricular arrhythmias. ( Pritchett, EL; Wilkinson, WE, 1991) |
| " Programmed electrical stimulation using up to three closely coupled premature stimuli and burst pacing was used to test the inducibility of arrhythmias both during control and administration of 1 micrograms/ml flecainide." | 3.68 | Proarrhythmic effects of flecainide. Experimental evidence for increased susceptibility to reentrant arrhythmias. ( Allessie, M; Boersma, L; Brugada, J; Kirchhof, C, 1991) |
| "The arrhythmogenic effects of flecainide in atrial fibrillation and flutter were assessed in a consecutive material of 100 patients without severe heart failure (NYHA class I or II)." | 3.68 | Flecainide acetate in atrial flutter and fibrillation. The arrhythmogenic effects. ( Hansen, FA; Pedersen, AK; Rasmussen, J; Sihm, I; Thygesen, K, 1990) |
| "To assess the efficacy of encainide and flecainide in treating patients with sustained ventricular arrhythmias." | 3.68 | Inefficacy and proarrhythmic effects of flecainide and encainide for sustained ventricular tachycardia and ventricular fibrillation. ( Eldar, M; Franz, MR; Griffin, JC; Herre, JM; Oeff, M; Scheinman, MM; Titus, C, 1990) |
| " Coadministration of amiodarone, and, moreover, the presence of heart failure increase the C/D ratio, from 2." | 3.68 | Flecainide acetate dose-concentration relationship in cardiac arrhythmias: influence of heart failure and amiodarone. ( Coumel, P; Denjoy, I; Leclercq, JF; Mentré, F, 1990) |
| "During a one-week short-term in-hospital period, 60 patients with chronic ventricular arrhythmias were treated with 200 mg flecainide twice a day." | 3.67 | Flecainide: one-year efficacy in patients with chronic ventricular arrhythmias. ( Balakumaran, K; Hagemeijer, F; Hugenholtz, PG; Jovanovic, A; Lubsen, J; Polak, BC; Roelandt, J; ten Cate, FJ; Vanhaleweyk, G; Withagen, A, 1984) |
| " In these models it is more potent than lidocaine, procainamide and quinidine, as well as a number of investigational agents, and is active against both ventricular and supraventricular arrhythmias from a number of causes." | 3.67 | Antiarrhythmic and electrophysiologic actions of flecainide in animal models. ( Banitt, EH; Kvam, DC; Schmid, JR, 1984) |
| "Flecainide acetate was evaluated in a placebo-controlled, dose-ranging study performed in patients with stable, high-frequency ventricular arrhythmias." | 3.67 | Flecainide dose-response relations in stable ventricular arrhythmias. ( Duff, HJ; Roden, DM; Siddoway, LA; Woosley, RL, 1984) |
| "The efficacy and safety of oral flecainide for treatment of ventricular arrhythmias were assessed during a 3-day period in patients with various cardiac diseases." | 3.67 | Oral flecainide for suppression of ventricular arrhythmias. ( Balakumaran, K; Hugenholtz, PG; Lubsen, J; Roelandt, J; Vanhaleweyk, G, 1984) |
| "The long-term efficacy and safety of flecainide (100 to 200 mg twice a day) were evaluated in 21 patients with high-grade, chronic ventricular arrhythmias who responded to and tolerated flecainide at a preliminary evaluation (200 mg, single oral dose)." | 3.67 | Efficacy and safety of flecainide in low-risk patients with chronic ventricular arrhythmias: a two-year follow-up. ( Bonazzi, O; Facchini, M; Priori, SG; Schwartz, PJ; Songa, V; Varisco, T, 1989) |
| "Drug efficacy and pharmacokinetics were assessed in 63 patients, aged 5 days to 30 years (mean 8 years), who received flecainide acetate for control of resistant arrhythmias." | 3.67 | Flecainide acetate for resistant arrhythmias in the young: efficacy and pharmacokinetics. ( Fredell, P; Garson, A; Gothing, C; McQuinn, RL; Perry, JC; Smith, RT, 1989) |
| "The properties of a class 1c antiarrhythmic drug, flecainide, were examined using 3 canine ventricular arrhythmia models: (1) digitalis-, (2) adrenaline- and (3) two-stage coronary ligation-induced arrhythmias." | 3.67 | Antiarrhythmic effects of the class 1c antiarrhythmic drug, flecainide, on canine ventricular arrhythmia models. ( Akiyama, K; Hashimoto, K, 1989) |
| "In order to assess the value of the various atrial pacing techniques employed to evaluate the anterograde conduction of the accessory pathway and the effect of antiarrhythmic agents in Wolff-Parkinson-White syndrome, transesophageal atrial pacing was performed in 12 patients before and during treatment with oral flecainide acetate in doses of 200 mg per day." | 3.67 | [Value of transesophageal auricular stimulation for evaluating the accessory pathway and effect of treatment in Wolf-Parkinson-White syndrome]. ( Bareiss, P; Facello, A; Kieny, JR; Kraenner, C; Mossard, JM; Roul, G; Sacrez, A, 1989) |
| "Flecainide has been reported to be effective in suppressing chronic ventricular arrhythmias in clinical studies, but the electrophysiological mechanisms of its action are not understood." | 3.67 | Electrophysiological effects of flecainide in a canine 7 day old myocardial infarction model. ( Hosokawa, M; Miyazaki, T; Nakamura, Y; Ogawa, S; Sakai, T; Sakurai, K, 1989) |
| "A 65 year old man with recurrent ventricular tachyarrhythmias post myocardial infarction developed dysarthria and visual hallucinations due to flecainide toxicity." | 3.67 | Dysarthria and visual hallucinations due to flecainide toxicity. ( Mackenzie, S; Ramhamadany, E; Ramsdale, DR, 1986) |
| "Definitions of proarrhythmia, including clinical consequence, were applied to the flecainide and encainide data bases to determine risk factors for serious proarrhythmic events or deaths." | 3.67 | Risk factors for the development of proarrhythmic events. ( Morganroth, J, 1987) |
| "Thirty-nine patients with symptomatic ectopic atrial tachycardia (9 paroxysmal, of which 5 were incessant) and atrial fibrillation (AF) (25 paroxysmal, 5 chronic) were treated with oral flecainide acetate (100 to 400 mg/day)." | 3.67 | Efficacy and safety of flecainide acetate for atrial tachycardia or fibrillation. ( Berns, E; Dougherty, AH; Jeang, MK; Jenkins, M; Naccarelli, GV; Rinkenberger, RL, 1987) |
| "Plasma flecainide concentrations were measured in 10 patients with acute myocardial infarction." | 3.67 | Plasma flecainide concentrations following acute myocardial infarction. ( Bhamra, R; Holt, DW; Jackson, G; Johnston, A; Ong, ML, 1987) |
| "Oral flecainide was administered to 98 patients with arrhythmias regarded as resistant to other antiarrhythmic agents: quinidines (82), propafenone (40), beta-blockers (30), amiodarone alone (38) or combined with a class I compound (19)." | 3.67 | [Oral flecainide in the treatment of refractory arrhythmias. Long-term follow-up of 98 patients]. ( Benchimol, D; Blanchot, P; Haissaguerre, M; Le Métayer, P; Regaudie, JJ; Warin, JF, 1987) |
| "A two-part pharmacokinetic approach was used to prospectively develop and test intravenous flecainide infusion regimens for the acute therapy for ventricular arrhythmias." | 3.67 | The development and testing of intravenous dosing regimens: application to flecainide for the suppression of ventricular arrhythmias. ( Bergstrand, RH; Conard, GJ; Kvam, D; Roden, DM; Siddoway, LA; Thompson, KA; Wang, T; Woosley, RL, 1988) |
| "We treated 22 children, aged 3 days to 16 years 6 months (median 11 years 1 month), with flecainide for a variety of arrhythmias where a Class I agent was indicated." | 3.67 | Experience with flecainide for the treatment of cardiac arrhythmias in children. ( Curry, PV; Holt, DW; Jones, OD; Ladusans, EJ; Priestley, KA; Rosenthal, E; Tynan, MJ, 1988) |
| "The effect of flecainide in 24 patients with inducible sustained ventricular arrhythmia and a history of remote myocardial infarction was determined." | 3.67 | Flecainide: steady state electrophysiologic effects in patients with remote myocardial infarction and inducible sustained ventricular arrhythmia. ( Greenspan, AM; Horowitz, LN; Morganroth, J; Senior, S; Spielman, SR; Webb, CR, 1986) |
| "Ninety-four patients with ventricular tachycardia (VT), 49 with sustained and 45 with nonsustained VT, who had been refractory to or intolerant of other antiarrhythmic agents were treated in a multicenter, open-label study with flecainide acetate." | 3.67 | Treatment of resistant ventricular tachycardia with flecainide acetate. Flecainide Ventricular Tachycardia Study Group. ( , 1986) |
| " This study assessed in 1,330 patients followed up for 292 +/- 393 days the predictive value for cardiovascular safety of a system by which patients were classified according to ventricular arrhythmias on entry, presence or absence of organic heart disease and drug dose for flecainide acetate." | 3.67 | Classification by type of ventricular arrhythmia predicts frequency of adverse cardiac events from flecainide. ( Anderson, JL; Gentzkow, GD; Morganroth, J, 1986) |
| "The objective of this study was to evaluate the haemodynamic and antiarrhythmic effects of flecainide acetate in patients with heart failure." | 3.67 | Haemodynamic and antiarrhythmic effects of intravenous flecainide acetate in chronic congestive heart failure. ( Dijk, A; Dunselman, PH; Kingma, JH; Lie, KI; van Wijk, LM; Wesseling, H, 1985) |
| "In a prospective study of 10 patients with chronic ventricular arrhythmias, flecainide 50mg tid and propranolol 20mg tid were administered, alone and in combination, in a crossover design." | 3.67 | Antiarrhythmic therapy with flecainide in combination and comparison with propranolol. ( Scheininger, M; Stern, H; Theisen, F; Theisen, K, 1985) |
| "The efficacy of the new class Ic anti-arrhythmic (aa) drug, Flecainide, has been evaluated in patients (pts) affected by frequent and/or severe chronic ventricular arrhythmias (VA), as assessed by 24 hours Holter monitoring and maximal exercise stress testing." | 3.67 | [Evaluation of flecainide in the therapy of chronic ventricular arrhythmia using the acute oral load method]. ( Bonazzi, O; Cuspidi, C; Facchini, M; Priori, S; Schwartz, PJ; Varisco, T; Zuanetti, G, 1985) |
| "After an initial pilot study in five patients, the effect of flecainide on chronic ventricular arrhythmias was tested during 48-hour oral administration of 250 mg twice a day in nine further patients with previously drug-resistant chronic, stable ventricular arrhythmias." | 3.66 | [Effect of flecainide on chronic ventricular arrhythmias (author's transl)]. ( Abendroth, RR; Bluschke, V; Breithardt, G; Seipel, L, 1982) |
| "AFL accounts for 30% of fetal tachyarrhythmias, 11% to 18% of neonatal tachyarrhythmias, and 8% of supraventricular tachyarrhythmias in children older than 1 year of age." | 2.82 | Atrial Flutter in Pediatric Patients. ( Drago, F; Tamborrino, PP, 2022) |
| "The short QT syndrome is characterized by familial sudden death, short refractory periods, and inducible ventricular fibrillation." | 2.71 | Short QT Syndrome: a familial cause of sudden death. ( Bianchi, F; Borggrefe, M; Gaita, F; Giustetto, C; Grossi, S; Riccardi, R; Richiardi, E; Schimpf, R; Wolpert, C, 2003) |
| "Baseline data from the Cardiac Arrhythmia Suppression Trial were used to define several categories of heart failure and to relate both the resulting categories and ejection fraction to arrhythmia suppression and mortality using logistic and survival regression analytic methodologies." | 2.68 | Relations between heart failure, ejection fraction, arrhythmia suppression and mortality: analysis of the Cardiac Arrhythmia Suppression Trial. ( DeMaria, A; Gottlieb, S; Greene, HL; Hallstrom, A; Huther, M; Pratt, CM; Young, JB, 1995) |
| "The Cardiac Arrhythmia Suppression Trial-1, a pharmacologic test of the arrhythmia suppression and mortality hypothesis among postmyocardial infarction patients, allowed a prospective test of the relationship of distress, perceived support, social interaction, life stress, and other variables, to mortality, adjusting statistically for ejection fraction, arrhythmia rates, and other known risk factors for coronary heart disease." | 2.67 | Psychosocial predictors of mortality in the Cardiac Arrhythmia Suppression Trial-1 (CAST-1). ( Brooks, MM; Gorkin, L; Kellen, J; Morris, M; Pawitan, Y; Schoenberger, JA; Schron, EB; Shumaker, S; Verter, J; Wiklund, I, 1993) |
| "The Cardiac Arrhythmia Suppression Trial (CAST) was a study designed to test the hypothesis that suppression of ventricular premature complexes after a myocardial infarction would improve survival." | 2.67 | The Cardiac Arrhythmia Suppression Trial: first CAST ... then CAST-II. ( Greene, HL; Henthorn, RW; Katz, RJ; Roden, DM; Salerno, DM; Woosley, RL, 1992) |
| " Adverse events including death are more frequent in older patients taking study drugs (P less than 0." | 2.67 | Effects of advancing age on the efficacy and side effects of antiarrhythmic drugs in post-myocardial infarction patients with ventricular arrhythmias. The CAST Investigators. ( Akiyama, T; Barker, AH; Campbell, WB; Friedman, L; Josephson, RA; Keller, M; Papa, L; Pawitan, Y; Rubbert, P, 1992) |
| " At the dosage used side effects related to flecainide or digoxin were not observed." | 2.67 | Prevention of arrhythmias after noncardiac thoracic operations: flecainide versus digoxin. ( Biollaz, J; Borgeat, A; Cavin, R; Munafo, A; Petropoulos, P; Schwander, D, 1991) |
| "Patients whose arrhythmias were suppressed were randomized in the main study and those whose arrhythmias were partially suppressed were randomized in a substudy." | 2.67 | Events in the Cardiac Arrhythmia Suppression Trial (CAST): mortality in the entire population enrolled. ( Bigger, JT; Epstein, AE; Hallstrom, AP; Reynolds-Haertle, RA; Romhilt, DW; Wyse, DG, 1991) |
| "The Cardiac Arrhythmia Suppression Trial (CAST) is a randomized, placebo-controlled, double-blind, multicenter clinical trial involving 27 centers and more than 100 hospitals in North America and Europe to test the 1-tailed hypothesis that suppression of ventricular arrhythmias in patients with left ventricular dysfunction after myocardial infarction will reduce arrhythmic death." | 2.67 | Implications of the Cardiac Arrhythmia Suppression Trial for antiarrhythmic drug treatment. ( Bigger, JT, 1990) |
| "The Cardiac Arrhythmia Suppression Trial (CAST) is a randomized, placebo-controlled, double-blind, international, multicenter clinical trial to determine whether suppression of ventricular arrhythmias after myocardial infarction with long-term antiarrhythmic drug treatment will reduce arrhythmic death." | 2.67 | Clinical aspects of trial design: what can we expect from the cardiac arrhythmia suppression trial? ( Bigger, JT, 1990) |
| "Flecainide was well tolerated and no adverse effects were reported." | 2.66 | Flecainide and cardiac dysrhythmias during dental extraction under anaesthesia. ( Clyburn, PA; Fassoulaki, A; Rosen, M; Webster, J, 1989) |
| "Cardiac arrhythmias are a frequent complication after thoracic operations." | 2.66 | Prevention of arrhythmias by flecainide after noncardiac thoracic surgery. ( Bayer-Berger, M; Biollaz, J; Borgeat, A; Chapuis, G; Chioléro, R; Kappenberger, L, 1989) |
| " During a double-blind drug and dose selection phase, investigators were permitted to change drug or dosage to achieve greater than or equal to 70% suppression in VPC frequency and greater than 90% suppression of runs of VPC with the exception of patients assigned to placebo, who continued receiving it." | 2.66 | Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: the CAPS. ( , 1988) |
| "Flecainide is an effective antiarrhythmic drug, but when administered orally in patients with left ventricular (LV) dysfunction, its effect on LV function is unknown." | 2.66 | Effect of flecainide on left ventricular ejection fraction. ( Amor, M; Auque, F; Bertrand, A; Brembilla-Perrot, B; Cherrier, F; Isaaz, K; Pernot, C; Terrier de la Chaise, A, 1987) |
| "Flecainide was as effective as the combination of digoxin and disopyramide and it acted significantly faster and was associated with fewer relapses." | 2.66 | Flecainide compared with a combination of digoxin and disopyramide for acute atrial arrhythmias after cardiopulmonary bypass. ( Campbell, TJ; Gavaghan, TP; Kelly, RP; Koegh, AM; Morgan, JJ; Thorburn, C, 1988) |
| "Many sudden deaths are presumed to be due to an arrhythmia, but the drugs best known for antiarrhythmic activity, the local anesthetic agents, have not been suitable prophylactic agents because of their toxicities and other undesirable pharmacologic characteristics." | 2.65 | Selection of an antiarrhythmic drug for a sudden-death-prevention trial. ( Duff, HJ; Oates, JA; Roden, DM; Woosley, RL, 1982) |
| "Flecainide was more effective than quinidine in suppressing chronic ventricular arrhythmias (especially complex forms), and thus is an important new antiarrhythmic agent." | 2.65 | Flecainide versus quinidine for treatment of chronic ventricular arrhythmias. A multicenter clinical trial. ( , 1983) |
| "Flecainide was more effective than quinidine (p less than 0." | 2.65 | Flecainide versus quinidine: results of a multicenter trial. ( Granrud, G; Hodges, M; Salerno, DM, 1984) |
| "Flecainide was injected intravenously at a rate of 20 mg per 2 min until complete disappearance of ventricular arrhythmias or up to a total dose not exceeding 200 mg." | 2.65 | Efficacy and tolerance of intravenous flecainide in patients with chronic high frequency ventricular arrhythmias. ( Andries, E; Kesteloot, H; Stroobandt, R; van Mieghem, W, 1984) |
| " It may therefore be possible to reduce the incidence of these complications by adapting dosage to the patient's clinical state and to the serum drug levels." | 2.65 | [Flecainide: a new antiarrhythmic agent]. ( Coumel, P; Leclercq, JF, 1983) |
| "Flecainide thus appears to be a highly effective and well-tolerated antiarrhythmic agent with favorable pharmacokinetics." | 2.65 | Oral flecainide acetate for the treatment of ventricular arrhythmias. ( Anderson, JL; Chang, SF; Conard, GJ; Johnson, TA; Kvam, DC; Perry, BA; Pitt, B; Stewart, JR; Van Hamersveld, DD, 1981) |
| " Twice-daily dosing (average daily dose 436 mg) completely suppressed all ventricular ectopic activity in five of 11 patients; average suppression in the 11 patients was 96." | 2.65 | Suppression of ventricular ectopic depolarizations by flecainide acetate, a new antiarrhythmic agent. ( Asinger, RW; Conard, GJ; Granrud, G; Haugland, JM; Hodges, M; Krejci, J; Mikell, FL, 1982) |
| "The nature of an arrhythmia and of individual patient factors change over time, requiring a flexible approach to long-term treatment that may be defined only after months or years." | 2.39 | Atrial fibrillation: maintenance of sinus rhythm versus rate control. ( Camm, AJ; Sopher, SM, 1996) |
| "Current management of ventricular arrhythmias are considered in the light of these findings." | 2.38 | Treatment of ventricular arrhythmias after CAST. ( Tonkin, AM, 1992) |
| " Flecainide appeared to be safe (no deaths with usual oral dosing, < 1% serious proarrhythmia) and effective (73% to 100% control, depending on mechanism) in children with supraventricular tachycardia." | 2.38 | Flecainide acetate for treatment of tachyarrhythmias in children: review of world literature on efficacy, safety, and dosing. ( Garson, A; Perry, JC, 1992) |
| "Amiodarone was also more beneficial than individual antiarrhythmic therapy (mortality 10/100 patients, 10%)." | 2.38 | [What is the latest in anti-arrhythmia therapy?]. ( Gloor, HO, 1991) |
| "Benign arrhythmias occur in the setting of structurally normal hearts and do not require therapy unless associated with debilitating symptoms." | 2.38 | Clinical implications of new studies in the treatment of benign, potentially malignant and malignant ventricular arrhythmias. ( Anderson, JL, 1990) |
| "These arrhythmias are divided in 31 atrial fibrillation, 11 tachy-systoles, 18 atrial flutters." | 2.38 | [Comparative study of cibenzoline and flecainide administered via an intravenous route in reducing auricular arrhythmia]. ( Bajolet, A; Chabert, JP; Chapoutot, L; Ehrhard, V; Laudinat, JM; Metivet, F; Metz, D; Pollet, E; Taupin, JM, 1990) |
| "The Cardiac Arrhythmia Suppression Trial (CAST) has led to serious reconsideration of both the benefit-risk ratio of antiarrhythmic drug therapy and the appropriate therapeutic approach to various cardiac arrhythmias." | 2.38 | Reassessment of benefit-risk ratio and treatment algorithms for antiarrhythmic drug therapy after the cardiac arrhythmia suppression trial. ( Anderson, JL, 1990) |
| "Flecainide is a new antiarrhythmic drug that may soon be released for general use." | 2.37 | A proposal for the clinical use of flecainide. ( Anderson, JL; Crevey, BJ; Stewart, JR, 1984) |
| " Serious adverse reactions necessitate a change in antiarrhythmic therapy, as opposed to lowering drug dosage to an ineffective level." | 2.37 | Antiarrhythmic drug therapy. Recent advances and current status. ( Somberg, J, 1985) |
| "The frequency of ventricular arrhythmias increases with age." | 2.37 | Cardiac arrhythmias in the elderly: antiarrhythmic drug treatment. ( Morganroth, J; Nestico, PF, 1986) |
| "While treatment of ventricular arrhythmias is completely justifiable for patients with symptoms, their use to prevent sudden cardiac death has not yet been established." | 2.37 | Antiarrhythmic agents for chronic ventricular arrhythmias. ( Morganroth, J; Nestico, PF, 1987) |
| " Bioavailability of encainide ranges from 7% to 82%, whereas that of flecainide is 90% to 95%." | 2.37 | Encainide hydrochloride and flecainide acetate: two class 1c antiarrhythmic agents. ( Chase, SL; Sloskey, GE, 1987) |
| "Flecainide acetate is a new class 1 c antiarrhythmic drug." | 2.37 | Flecainide: a new antiarrhythmic drug. ( Baur, HR; Mueller, RA, 1986) |
| "Flecainide has been shown to be a relatively safe and effective antiarrhythmic agent." | 2.37 | Flecainide: a new agent for the treatment of ventricular arrhythmias. ( Grubb, BP; Tilley-Gray, B, 1986) |
| "Flecainide is a Class I antiarrhythmic drug of the local anaesthetic type." | 2.37 | Flecainide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy. ( Heel, RC; Holmes, B, 1985) |
| "Patients with unexplained ventricular arrhythmias (UVA) were identified as those with no structural heart disease on echocardiogram, no obstructive coronary disease, and no clear diagnostic features on ECG." | 1.91 | Diagnostic evaluation of unexplained ventricular tachyarrhythmias in younger adults. ( Kistler, P; Ling, LH; Mariani, J; Patel, H; Prabhu, S; Shirwaiker, A; Sugamar, H; Voskoboinik, A; William, J; Xiao, X, 2023) |
| "A novel familial arrhythmia syndrome, cardiac ryanodine receptor (RyR2) calcium release deficiency syndrome (CRDS), has recently been described." | 1.72 | Provocation Testing and Therapeutic Response in a Newly Described Channelopathy: RyR2 Calcium Release Deficiency Syndrome. ( Chen, SRW; Dreau, HMP; Ginks, MR; Guo, W; Li, Y; McGuire, K; Ormerod, JOM; Ormondroyd, E; Rajappan, K; Sarton, CNS; Taylor, J; Taylor, JC; Wang, R; Watkins, H; Wei, J, 2022) |
| "Flecainide is a 1C antidysrhythmic that is primarily used for ventricular tachycardia or premature ventricular contractions when other treatment is ineffective." | 1.72 | Flecainide poisoning and prolongation of elimination due to alkalinization. ( Georgakakos, PK; McCabe, DJ; Radke, JB; Walsh, RD; Wilson, BZ, 2022) |
| "Tachycardia is characterized by high beating rates that can lead to life-threatening fibrillations." | 1.72 | Functional evaluation of the tachycardia patient-derived iPSC cardiomyocytes carrying a novel pathogenic SCN5A variant. ( Akdeniz, C; Cagavi, E; Goktas Sahoglu, S; Kazci, YE; Torun, T; Tuncay, E; Tuzcu, V, 2022) |
| "Sudden cardiac death from ventricular arrhythmias is more common in adult patients with with heart failure compared with pediatric patients with heart failure." | 1.48 | Acute isoproterenol leads to age-dependent arrhythmogenesis in guinea pigs. ( Chau, S; Miyamoto, SD; Nau, S; Phillips, EK; Stauffer, BL; Sucharov, CC; Tompkins, C; Wilson, CE; Woulfe, KC; Zang, S, 2018) |
| "Fibrosis was triggered by transforming growth factor β (TGF-β) pathway activation." | 1.46 | Transforming growth factor β receptor inhibition prevents ventricular fibrosis in a mouse model of progressive cardiac conduction disease. ( Baró, I; Cerpa, CO; Charpentier, F; Colledge, WH; Derangeon, M; Girardeau, A; Grace, AA; Huang, CLH; Jagu, B; Montnach, J; Patin, J; Toumaniantz, G, 2017) |
| "Flecainide is a safe and effective antiarrhythmic medication, even for children with underlying CHD." | 1.46 | The Safety and Effectiveness of Flecainide in Children in the Current Era. ( Cunningham, T; Franciosi, S; Jeremiasen, I; Morris, R; Sanatani, S; Sherwin, E; Uzun, O; Wong, A, 2017) |
| "However, the mechanisms of cardiac arrhythmias in DM1 are unknown." | 1.42 | Abnormal sodium current properties contribute to cardiac electrical and contractile dysfunction in a mouse model of myotonic dystrophy type 1. ( Algalarrondo, V; Azibi, K; Balse, E; Beldjord, C; Coulombe, A; Duboc, D; Eymard, B; Fischmeister, R; Gourdon, G; Hatem, SN; Sebag, F; Wahbi, K, 2015) |
| "Unexplained cardiac arrest (UCA) can be caused by low-penetrance genetic disorders." | 1.42 | Diagnostic Approach to Unexplained Cardiac Arrest (from the FIVI-Gen Study). ( Álvarez, M; Cózar, R; Domingo, D; Fernández Pastor, J; Gimeno, JR; Grima, EZ; Heras, RP; Jiménez-Jáimez, J; Mazuelos, F; Monserrat, L; Moriña, P; Ortiz-Genga, M; Peinado, R; Sánchez Muñoz, JJ; Segura, F; Tercedor, L, 2015) |
| "We wanted to analyze ventricular arrhythmia induced by local left ventricular stretch in order to find out, where arrhythmias originate and whether they can be prevented pharmacologically." | 1.40 | Arrhythmogenic effects by local left ventricular stretch: effects of flecainide and streptomycin. ( Dhein, S; Dohmen, PM; Englert, C; Kostelka, M; Mohr, FW; Riethdorf, S, 2014) |
| "The vast majority of paediatric arrhythmias concerns children older than 1 year and patients with grown-up congenital heart disease." | 1.40 | How are arrhythmias managed in the paediatric population in Europe? Results of the European Heart Rhythm survey. ( Blomström-Lundqvist, C; Chen, J; Hernández-Madrid, A; Hocini, M; Pison, L; Potpara, T, 2014) |
| "Tachyarrhythmias are more common in the Brugada syndrome, particularly following pharmacological challenge, previously modelled using Scn5a(+/-) murine hearts." | 1.39 | Action potential wavelength restitution predicts alternans and arrhythmia in murine Scn5a(+/-) hearts. ( Grace, AA; Guzadhur, L; Huang, CL; Matthews, GD; Sabir, IN, 2013) |
| " This case report describes a novel approach to fetal cardioversion using oral maternal bolus dosing of flecainide." | 1.39 | A novel method of fetal cardioversion. ( Sanghavi, DM, 2013) |
| "Flecainide is a class IC antidysrhythmic primarily indicated for ventricular dysrhythmias and supraventricular tachycardia (SVT)." | 1.39 | A case of near-fatal flecainide overdose in a neonate successfully treated with sodium bicarbonate. ( Hoffman, RS; Jang, DH; Nelson, LS, 2013) |
| "Flecainide was found to prolong ventricular repolarization, with effect being greater at the left ventricular compared with the right ventricular epicardium." | 1.38 | Flecainide-induced proarrhythmia is attributed to abnormal changes in repolarization and refractoriness in perfused guinea-pig heart. ( Osadchii, OE, 2012) |
| "Pharmacological management of cardiac arrhythmia has failed because it is not possible to predict how drugs that target cardiac ion channels, and have intrinsically complex dynamic interactions with ion channels, will alter the emergent electrical behavior generated in the heart." | 1.37 | A computational model to predict the effects of class I anti-arrhythmic drugs on ventricular rhythms. ( Bankston, JR; Bayer, JD; Christini, DJ; Clancy, CE; Jeng, MT; Kang, C; Kass, RS; Moreno, JD; Ripplinger, CM; Trayanova, NA; Wang, L; Yang, PC; Zhu, ZI, 2011) |
| "We discovered that flecainide prevents arrhythmias in a mouse model of CPVT by inhibiting cardiac ryanodine receptor-mediated Ca(2+) release and thereby directly targeting the underlying molecular defect." | 1.35 | Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. ( Chopra, N; Davies, SS; Duff, HJ; Hwang, HS; Knollmann, BC; Laver, D; Roach, DE; Roden, DM; Watanabe, H; Wilde, AA, 2009) |
| "Flecainide has been shown to reduce salt absorption in animal bowel." | 1.34 | Flecainide cardiotoxicity precipitated by electrolyte imbalance. Caution with thiazide diuretics. ( Khavandi, A; Walker, PR, 2007) |
| "Phase-2 ventricular arrhythmias occur during infarct evolution." | 1.33 | Actions of flecainide on susceptibility to phase-2 ventricular arrhythmias during infarct evolution in rat isolated perfused hearts. ( Clements-Jewery, H; Curtis, MJ; Kabra, R; Kanaganayagam, GS, 2006) |
| "Tachycardia was observed in 15% of cases (three cases of supraventricular tachycardia [SVT] and two cases of auricular flutter [AF])." | 1.31 | [Fetal arrhythmias: diagnosis, prognosis, treatment; apropos of 33 cases]. ( Dubos, JP; Dufour, P; Puech, F; Subtil, D; Vaast, P; Vaksmann, G; Valat, AS; Vautier-Rit, S, 2000) |
| "Flecainide was equi-effective at low and high concentrations, with VF incidence reduced from 92% to 17% (p < 0." | 1.31 | Limited antifibrillatory effectiveness of clinically relevant concentrations of class I antiarrhythmics in isolated perfused rat hearts. ( Curtis, MJ; Farkas, A, 2002) |
| "micrograms -1 after acute dosing versus 3." | 1.29 | Flecainide acetate: concentration-response relationships for antiarrhythmic and electrocardiographic effects. ( Biffi, M; Boriani, G; Calliva, R; Capucci, A; Magnani, B; Santarelli, A; Strocchi, E, 1993) |
| "Flecainide was found to induce extrasystolic activity more readily than other sodium blockers." | 1.29 | Flecainide-induced arrhythmia in canine ventricular epicardium. Phase 2 reentry? ( Antzelevitch, C; Krishnan, SC, 1993) |
| "Flecainide acetate was administered at a dose of 100 mg twice daily to 15 patients with drug-resistant ventricular ectopy." | 1.28 | Oral flecainide for the treatment of drug-resistant ventricular ectopy. ( Sclarovsky, S; Stein, S; Strasberg, B, 1990) |
| "An example from the Cardiac Arrhythmia Suppression Trial (CAST) illustrates what we term the 'healthy responder' phenomenon." | 1.28 | The healthy responder phenomenon in non-randomized clinical trials. CAST Investigators. ( Greene, HL; Hallstrom, AP; Huther, ML, 1991) |
| "Oral flecainide treatment was given to five patients who were refractory to conventional antiarrhythmic agents." | 1.28 | [Effects of oral flecainide treatment of refractory tachyarrhythmias]. ( Hiraoka, M; Hiyoshi, Y; Motomiya, T; Sakurada, H; Sugiura, M; Tejima, T; Tokuyasu, Y; Watanabe, K; Yanase, O, 1990) |
| "Flecainide (F) is a new antiarrhythmic agent recently introduced into clinical practice." | 1.28 | [Kinetics of intravenously administered flecainide in patients with acute myocardial infarct]. ( Carelli, M; Di Marcotullio, G; Giampaolo, P; Malinconico, U; Milazzotto, F; Polizzi, CA; Tubaro, M, 1989) |
| "When amiodarone was not employed, as a first choice, in conformity with a specific protocol, it was utilized as a second choice after verapamil or flecainide." | 1.28 | [Supraventricular tachyarrhythmia of recent onset in the absence of documented cardiac pathology: different therapeutic approaches]. ( Bechi, S; Cordoni, M; Franchini, C; Mazza, F; Micheli, G; Scalzini, A, 1989) |
| "1." | 1.28 | A dual model for cardiac arrhythmias: coexistence of re-entry and abnormal automaticity and effects of antiarrhythmic agents. ( Hunter, T; Proakis, A; Wu, KM, 1989) |
| " The administration of flecainide, dosage 1." | 1.28 | [A case of atrial paralysis during the use of intravenous flecainide acetate]. ( Pardini, E; Tognarini, S, 1989) |
| "For single ventricular extrasystoles, doublets and triplets, nine very good results (80 to 100 per cent reduction of arrhythmia) and four 50 to 80 per cent reductions in ventricular prematurity were obtained." | 1.27 | [Study of flecainide in the treatment of ventricular arrhythmia]. ( Errera, J; Hug, C; Koliopoulos, N; Puech, P; Tardy, C, 1983) |
| "Two patients who developed ventricular arrhythmias were taking other antiarrhythmic agents, and in this series proarrhythmic effects occurred with both normal and high flecainide concentrations." | 1.27 | Proarrhythmic effects of the new antiarrhythmic agent flecainide acetate. ( Banim, SO; Bexton, RS; Camm, AJ; Hellestrand, KJ; Nathan, AW; Spurrell, RA, 1984) |
| " The most frequently reported extracardiac adverse experiences were dizziness (30%) and visual disturbances (28%), often occurring in tandem." | 1.27 | Extracardiac adverse effects of flecainide. ( Gentzkow, GD; Sullivan, JY, 1984) |
| "Flecainide was successful in the acute termination of 86% of orthodromic atrioventricular reentrant tachycardias." | 1.27 | Electrophysiologic effects of flecainide acetate on sinus node function, anomalous atrioventricular connections, and pacemaker thresholds. ( Bexton, RS; Camm, AJ; Hellestrand, KJ; Nathan, AW, 1984) |
| "In patients with chronic ventricular arrhythmias, an increase in VPC frequency developed in 0 to 4% of patients, compared with 1 to 8% of patients who received quinidine and 2% who received encainide, another class IC agent." | 1.27 | Flecainide: its proarrhythmic effect and expected changes on the surface electrocardiogram. ( Horowitz, LN; Morganroth, J, 1984) |
| " The extended half-life of this new agent (about 20 hours in cardiac patients) may allow a convenient twice-daily dosage schedule." | 1.27 | Use of flecainide acetate in the treatment of premature ventricular contractions. ( Abate, C; Abitbol, H; Beilis, P; Califano, JE; Castellanos, H, 1983) |
| "Flecainide acetate is a recently introduced, class 1 antiarrhythmic agent that is highly effective in the treatment of ventricular and atrioventricular/nodal reentrant tachycardias." | 1.27 | Pacing failure due to flecainide acetate. ( Clarke, LM; James, MA; Papouchado, M; Walker, PR, 1985) |
| " Flecainide acetate, at a reduced dosage of 100 mg twice daily, is effective in both aspects, markedly decreasing PVC frequency and preventing VT induction at PES testing." | 1.27 | Flecainide: a new antiarrhythmic agent. ( Somberg, JC; Tepper, D, 1986) |
| "Disopyramide was only modestly active, while flecainide and encainide had the least favorable profiles of effect in suppressing re-entry arrhythmias in this model." | 1.27 | Assessment of drug effects on spontaneous and induced ventricular arrhythmias in a 24-h canine infarction model. ( Gomoll, AW, 1987) |
| "Flecainide is a class I antiarrhythmic agent which depresses depolarization and conduction velocities in myocardial and Purkinje's fibres, thereby extending their refractory period." | 1.27 | [Anomalies of the T waves induced by flecainide]. ( Haïat, R; Halphen, C; Leroy, G; Stoltz, JP; Weingrod, M, 1988) |
| "Flecainide plasma levels were higher when associated with cardiovascular side effects (mean 1063 ng/ml; range 296 to 2050 ng/ml) than when no side effects occurred (mean 609 ng/ml; range 89 to 1508 ng/ml; P less than 0." | 1.27 | Pharmacodynamics and side effects of flecainide acetate. ( Berry, D; Erlien, D; Granrud, G; Hodges, M; Krejci, J; Larson, T; Salerno, DM; Sharkey, P, 1986) |
| "Oral amiodarone therapy was given to seven patients already taking oral flecainide regularly." | 1.27 | Flecainide and amiodarone interaction. ( Kim, SS; Lal, R; Ruffy, R; Schechtman, K; Shea, P, 1986) |
| "Two patients who developed ventricular arrhythmias were taking other antiarrhythmic agents, and in this series proarrhythmic effects occurred with both normal and high flecainide concentrations." | 1.27 | The proarrhythmic effects of flecainide. ( Bexton, RS; Camm, AJ; Hellestrand, KJ; Nathan, AW; Spurrell, RA, 1985) |
| "Flecainide appears to be an effective agent for the conversion to sinus rhythm of atrial fibrillation and supraventricular tachycardias." | 1.27 | Conversion of supraventricular arrhythmias to sinus rhythm using flecainide. ( Duc, J; Finci, L; Goy, JJ; Grbic, M; Hurni, M; Maendly, R; Sigwart, U, 1985) |
| "Flecainide was given intravenously in a dose of 1 mg/kg and 2 mg/kg." | 1.26 | [Electrophysiological effects of the new antiarrhythmic drug flecainide (R 818) in man (author's transl)]. ( Abendroth, RR; Breithardt, G; Seipel, L, 1981) |
| "If the predrug arrhythmia(s) was not completely suppressed, additional boluses of 0." | 1.26 | Antiarrhythmic effects of flecainide. ( Somani, P, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 149 (42.45) | 18.7374 |
| 1990's | 106 (30.20) | 18.2507 |
| 2000's | 29 (8.26) | 29.6817 |
| 2010's | 51 (14.53) | 24.3611 |
| 2020's | 16 (4.56) | 2.80 |
| Authors | Studies |
|---|---|
| Phillips, GB | 1 |
| Morgan, TK | 1 |
| Nickisch, K | 1 |
| Lind, JM | 1 |
| Gomez, RP | 1 |
| Wohl, RA | 1 |
| Argentieri, TM | 1 |
| Sullivan, ME | 1 |
| Johnson, RE | 1 |
| Baizman, ER | 1 |
| Becker, C | 1 |
| Bohnet, EA | 1 |
| Bell, RH | 1 |
| Birsner, NC | 1 |
| Busacca, CA | 1 |
| Carabateas, PM | 1 |
| Chadwick, CC | 1 |
| Gruett, MD | 1 |
| Jia, L | 1 |
| Sun, H | 1 |
| Tunca Sahin, G | 1 |
| Beattie, RB | 1 |
| Uzun, O | 3 |
| Ormerod, JOM | 1 |
| Ormondroyd, E | 1 |
| Li, Y | 1 |
| Taylor, J | 1 |
| Wei, J | 1 |
| Guo, W | 1 |
| Wang, R | 1 |
| Sarton, CNS | 1 |
| McGuire, K | 1 |
| Dreau, HMP | 1 |
| Taylor, JC | 1 |
| Ginks, MR | 1 |
| Rajappan, K | 1 |
| Chen, SRW | 1 |
| Watkins, H | 1 |
| Cheung, CC | 1 |
| Scheinman, M | 1 |
| Lee, BK | 1 |
| McCabe, DJ | 1 |
| Walsh, RD | 1 |
| Georgakakos, PK | 1 |
| Radke, JB | 1 |
| Wilson, BZ | 1 |
| Osadchii, OE | 6 |
| Calloe, K | 1 |
| Geryk, M | 1 |
| Freude, K | 1 |
| Treat, JA | 1 |
| Vold, VA | 1 |
| Frederiksen, HRS | 1 |
| Broendberg, AK | 1 |
| Frederiksen, TC | 1 |
| Jensen, HK | 1 |
| Cordeiro, JM | 1 |
| Ryan, K | 1 |
| Benz, P | 1 |
| Zosel, A | 1 |
| Farkas, A | 2 |
| Theobald, J | 1 |
| Goktas Sahoglu, S | 1 |
| Kazci, YE | 1 |
| Tuncay, E | 1 |
| Torun, T | 1 |
| Akdeniz, C | 1 |
| Tuzcu, V | 2 |
| Cagavi, E | 1 |
| Drago, F | 2 |
| Tamborrino, PP | 1 |
| Hagino, M | 1 |
| Ota, C | 1 |
| Onoki, T | 1 |
| Iwasawa, S | 1 |
| Bhatt, H | 1 |
| Regan, W | 1 |
| Rosenthal, E | 4 |
| Bellsham-Revell, H | 1 |
| William, J | 1 |
| Xiao, X | 1 |
| Shirwaiker, A | 1 |
| Patel, H | 1 |
| Prabhu, S | 1 |
| Ling, LH | 1 |
| Sugamar, H | 1 |
| Mariani, J | 1 |
| Kistler, P | 1 |
| Voskoboinik, A | 1 |
| Candanedo Ocaña, F | 1 |
| Martín Toro, MA | 1 |
| Camacho Jurado, FJ | 1 |
| Martín Hidalgo, M | 1 |
| González Pérez, PJ | 1 |
| Herruzo Rojas, MS | 1 |
| Morales Ponce, FJ | 1 |
| Jee, G | 1 |
| Wong, A | 2 |
| Ofoe, V | 1 |
| Boglione, L | 1 |
| De Nicolò, A | 1 |
| Di Perri, G | 1 |
| D'Avolio, A | 1 |
| Kahr, PC | 1 |
| Moffett, BS | 1 |
| Miyake, CY | 1 |
| Kim, JJ | 1 |
| Valdes, SO | 1 |
| Salvage, SC | 1 |
| Gallant, EM | 1 |
| Fraser, JA | 1 |
| Huang, CL | 5 |
| Dulhunty, AF | 1 |
| Derangeon, M | 1 |
| Montnach, J | 1 |
| Cerpa, CO | 1 |
| Jagu, B | 1 |
| Patin, J | 1 |
| Toumaniantz, G | 1 |
| Girardeau, A | 1 |
| Huang, CLH | 1 |
| Colledge, WH | 1 |
| Grace, AA | 5 |
| Baró, I | 1 |
| Charpentier, F | 1 |
| Brisinda, D | 1 |
| Sorbo, AR | 1 |
| La Brocca, L | 1 |
| Fenici, R | 1 |
| Cunningham, T | 1 |
| Morris, R | 1 |
| Franciosi, S | 1 |
| Jeremiasen, I | 1 |
| Sherwin, E | 1 |
| Sanatani, S | 1 |
| Alsaied, T | 1 |
| Baskar, S | 1 |
| Fares, M | 1 |
| Alahdab, F | 1 |
| Czosek, RJ | 1 |
| Murad, MH | 1 |
| Prokop, LJ | 1 |
| Divanovic, AA | 1 |
| Markey, GC | 1 |
| Salter, N | 1 |
| Ryan, J | 1 |
| Chen, R | 1 |
| Chung, SH | 1 |
| Hemmeryckx, B | 1 |
| Feng, Y | 1 |
| Frederix, L | 1 |
| Lox, M | 1 |
| Trenson, S | 1 |
| Vreeken, R | 1 |
| Lu, HR | 3 |
| Gallacher, D | 1 |
| Ni, Y | 1 |
| Lijnen, HR | 1 |
| Woulfe, KC | 1 |
| Wilson, CE | 1 |
| Nau, S | 1 |
| Chau, S | 1 |
| Phillips, EK | 1 |
| Zang, S | 1 |
| Tompkins, C | 1 |
| Sucharov, CC | 1 |
| Miyamoto, SD | 1 |
| Stauffer, BL | 1 |
| Ellermann, C | 1 |
| Wolfes, J | 1 |
| Puckhaber, D | 1 |
| Bögeholz, N | 1 |
| Leitz, P | 1 |
| Lange, PS | 1 |
| Eckardt, L | 2 |
| Frommeyer, G | 1 |
| Matthews, GD | 1 |
| Guzadhur, L | 1 |
| Sabir, IN | 1 |
| Janson, CM | 1 |
| Poelzing, S | 2 |
| Shah, MJ | 1 |
| Dhein, S | 2 |
| Englert, C | 1 |
| Riethdorf, S | 1 |
| Kostelka, M | 1 |
| Dohmen, PM | 1 |
| Mohr, FW | 1 |
| Hernández-Madrid, A | 2 |
| Hocini, M | 1 |
| Chen, J | 2 |
| Potpara, T | 2 |
| Pison, L | 2 |
| Blomström-Lundqvist, C | 2 |
| Algalarrondo, V | 1 |
| Wahbi, K | 1 |
| Sebag, F | 1 |
| Gourdon, G | 1 |
| Beldjord, C | 1 |
| Azibi, K | 1 |
| Balse, E | 1 |
| Coulombe, A | 1 |
| Fischmeister, R | 1 |
| Eymard, B | 1 |
| Duboc, D | 1 |
| Hatem, SN | 1 |
| Bjerregaard Larsen, T | 1 |
| Estner, HL | 1 |
| Todd, D | 1 |
| Grazia Bongiorni, M | 1 |
| Happonen, JM | 1 |
| Blom, N | 1 |
| Celiker, A | 1 |
| Hebe, J | 1 |
| Janousek, J | 1 |
| Kornyei, L | 1 |
| Kriebel, T | 1 |
| Papagiannis, J | 1 |
| Paul, T | 1 |
| Pfammatter, JP | 1 |
| Savio-Galimberti, E | 1 |
| Knollmann, BC | 4 |
| Melgari, D | 1 |
| Zhang, Y | 1 |
| El Harchi, A | 1 |
| Dempsey, CE | 1 |
| Hancox, JC | 1 |
| Jiménez-Jáimez, J | 1 |
| Peinado, R | 1 |
| Grima, EZ | 1 |
| Segura, F | 1 |
| Moriña, P | 1 |
| Sánchez Muñoz, JJ | 1 |
| Mazuelos, F | 1 |
| Cózar, R | 1 |
| Gimeno, JR | 1 |
| Heras, RP | 1 |
| Monserrat, L | 1 |
| Domingo, D | 1 |
| Ortiz-Genga, M | 1 |
| Fernández Pastor, J | 1 |
| Álvarez, M | 1 |
| Tercedor, L | 1 |
| Robyns, T | 1 |
| Gallacher, DJ | 2 |
| Garweg, C | 1 |
| Ector, J | 1 |
| Willems, R | 1 |
| Janssens, S | 1 |
| Nuyens, D | 1 |
| Schmidt, JJ | 1 |
| Ramazan, L | 1 |
| Bockemeyer, C | 1 |
| Günter, HH | 1 |
| Martens-Lobenhoffer, J | 1 |
| Ganzenmüller, T | 1 |
| Bode-Böger, SM | 1 |
| Kielstein, JT | 1 |
| Ahn, J | 2 |
| Roh, SY | 1 |
| Lee, DI | 1 |
| Shim, J | 1 |
| Choi, JI | 1 |
| Kim, YH | 2 |
| Mahida, S | 1 |
| Derval, N | 1 |
| Preininger, MK | 1 |
| Jha, R | 1 |
| Maxwell, JT | 1 |
| Wu, Q | 1 |
| Singh, M | 1 |
| Wang, B | 1 |
| Dalal, A | 1 |
| Mceachin, ZT | 1 |
| Rossoll, W | 1 |
| Hales, CM | 1 |
| Fischbach, PS | 1 |
| Wagner, MB | 1 |
| Xu, C | 1 |
| Calkins, H | 1 |
| Watanabe, H | 2 |
| Chopra, N | 2 |
| Laver, D | 2 |
| Hwang, HS | 1 |
| Davies, SS | 2 |
| Roach, DE | 1 |
| Duff, HJ | 5 |
| Roden, DM | 10 |
| Wilde, AA | 3 |
| McBride, BF | 1 |
| Yang, T | 1 |
| Liu, K | 1 |
| Urban, TJ | 1 |
| Giacomini, KM | 1 |
| Kim, RB | 1 |
| Hilliard, FA | 1 |
| Steele, DS | 1 |
| Yang, Z | 1 |
| Le Marchand, SJ | 1 |
| Piston, DW | 1 |
| Huke, S | 1 |
| Lehnart, SE | 1 |
| Lederer, WJ | 1 |
| Hakim, P | 1 |
| Thresher, R | 1 |
| Larsen, AP | 1 |
| Olesen, SP | 1 |
| Grunnet, M | 1 |
| Rohrbacher, J | 1 |
| Vlaminckx, E | 1 |
| Van Ammel, K | 1 |
| Yan, GX | 1 |
| Kim, HS | 1 |
| Pak, HN | 1 |
| Park, JS | 1 |
| Kim, SS | 2 |
| Martin, CA | 2 |
| Barajas-Martinez, H | 1 |
| Hu, D | 1 |
| Ontiveros, G | 1 |
| Caceres, G | 1 |
| Desai, M | 1 |
| Burashnikov, E | 1 |
| Scaglione, J | 1 |
| Antzelevitch, C | 3 |
| van der Werf, C | 1 |
| Kannankeril, PJ | 1 |
| Sacher, F | 1 |
| Krahn, AD | 1 |
| Viskin, S | 1 |
| Leenhardt, A | 2 |
| Shimizu, W | 1 |
| Sumitomo, N | 2 |
| Fish, FA | 2 |
| Bhuiyan, ZA | 1 |
| Willems, AR | 1 |
| van der Veen, MJ | 1 |
| Laborderie, J | 1 |
| Haïssaguerre, M | 3 |
| Almroth, H | 1 |
| Andersson, T | 1 |
| Fengsrud, E | 1 |
| Friberg, L | 1 |
| Linde, P | 1 |
| Rosenqvist, M | 1 |
| Englund, A | 1 |
| Moreno, JD | 1 |
| Zhu, ZI | 1 |
| Yang, PC | 1 |
| Bankston, JR | 1 |
| Jeng, MT | 1 |
| Kang, C | 1 |
| Wang, L | 1 |
| Bayer, JD | 1 |
| Christini, DJ | 1 |
| Trayanova, NA | 1 |
| Ripplinger, CM | 1 |
| Kass, RS | 2 |
| Clancy, CE | 2 |
| Close, BR | 1 |
| Banks, CJ | 1 |
| Sanghavi, DM | 1 |
| Romero-Puche, AJ | 1 |
| Trigueros-Ruiz, N | 1 |
| Cerdán-Sánchez, MC | 1 |
| Pérez-Lorente, F | 1 |
| Roldán, D | 1 |
| Vicente-Vera, T | 1 |
| Jang, DH | 1 |
| Hoffman, RS | 1 |
| Nelson, LS | 1 |
| Belardinelli, L | 1 |
| Liu, G | 1 |
| Smith-Maxwell, C | 1 |
| Wang, WQ | 1 |
| El-Bizri, N | 1 |
| Hirakawa, R | 1 |
| Karpinski, S | 1 |
| Li, CH | 1 |
| Hu, L | 1 |
| Li, XJ | 1 |
| Crumb, W | 1 |
| Wu, L | 1 |
| Koltun, D | 1 |
| Zablocki, J | 1 |
| Yao, L | 1 |
| Dhalla, AK | 1 |
| Rajamani, S | 1 |
| Shryock, JC | 1 |
| Levis, JT | 1 |
| Apostolakis, S | 1 |
| Oeff, M | 2 |
| Tebbe, U | 1 |
| Fabritz, L | 1 |
| Breithardt, G | 5 |
| Kirchhof, P | 1 |
| Wehling, M | 1 |
| Rasheed, A | 1 |
| Simpson, J | 1 |
| Mok, NS | 1 |
| Priori, SG | 3 |
| Napolitano, C | 1 |
| Chan, NY | 1 |
| Chahine, M | 1 |
| Baroudi, G | 1 |
| Gaita, F | 3 |
| Giustetto, C | 2 |
| Bianchi, F | 2 |
| Wolpert, C | 3 |
| Schimpf, R | 3 |
| Riccardi, R | 1 |
| Grossi, S | 1 |
| Richiardi, E | 1 |
| Borggrefe, M | 3 |
| Calò, L | 1 |
| Brugada, R | 1 |
| van Loon, G | 1 |
| Blissitt, KJ | 1 |
| Keen, JA | 1 |
| Young, LE | 1 |
| Homma, M | 1 |
| Kuga, K | 1 |
| Doki, K | 1 |
| Katori, K | 1 |
| Yamaguchi, I | 1 |
| Sugibayashi, K | 1 |
| Kohda, Y | 1 |
| Malesker, MA | 1 |
| Sojka, SG | 1 |
| Fagan, NL | 1 |
| Razavi, M | 1 |
| Fukuda, K | 1 |
| Nakajima, T | 1 |
| Ong, BH | 1 |
| Kupershmidt, S | 1 |
| Fessel, J | 1 |
| Amarnath, V | 1 |
| Anderson, ME | 1 |
| Boyden, PA | 1 |
| Viswanathan, PC | 2 |
| Roberts, LJ | 1 |
| Balser, JR | 2 |
| Clements-Jewery, H | 1 |
| Kanaganayagam, GS | 1 |
| Kabra, R | 1 |
| Curtis, MJ | 2 |
| Pandya, B | 1 |
| Lambiase, PD | 1 |
| Ito, I | 1 |
| Hayashi, Y | 2 |
| Kawai, Y | 1 |
| Iwasaki, M | 1 |
| Takada, K | 2 |
| Kamibayashi, T | 2 |
| Yamatodani, A | 2 |
| Mashimo, T | 1 |
| Montagnac, R | 1 |
| Schoen, E | 1 |
| Aliouche, CP | 1 |
| Schillinger, F | 1 |
| Khavandi, A | 1 |
| Walker, PR | 2 |
| Milberg, P | 1 |
| Tegelkamp, R | 1 |
| Osada, N | 1 |
| Kaufman, ES | 1 |
| Sanna, GP | 1 |
| Woosley, RL | 6 |
| Oates, JA | 2 |
| Bluschke, V | 1 |
| Abendroth, RR | 2 |
| Seipel, L | 2 |
| Hug, C | 1 |
| Koliopoulos, N | 1 |
| Tardy, C | 1 |
| Errera, J | 1 |
| Puech, P | 2 |
| Hellestrand, KJ | 7 |
| Burnett, PJ | 1 |
| Milne, JR | 1 |
| Bexton, RS | 6 |
| Nathan, AW | 6 |
| Camm, AJ | 11 |
| Salerno, DM | 4 |
| Hodges, M | 4 |
| Granrud, G | 4 |
| Sharkey, P | 2 |
| Anderson, JL | 9 |
| Stewart, JR | 2 |
| Crevey, BJ | 1 |
| Hudak, JM | 1 |
| Banitt, EH | 2 |
| Schmid, JR | 2 |
| Singh, BN | 2 |
| Nademanee, K | 2 |
| Josephson, MA | 1 |
| Ikeda, N | 2 |
| Venkatesh, N | 1 |
| Kannan, R | 1 |
| Stroobandt, R | 1 |
| Andries, E | 1 |
| van Mieghem, W | 1 |
| Kesteloot, H | 1 |
| Leclercq, JF | 6 |
| Coumel, P | 6 |
| Kjekshus, J | 1 |
| Bathen, J | 1 |
| Orning, OM | 2 |
| Storstein, L | 1 |
| Mead, RH | 1 |
| Harrison, DC | 1 |
| Fontaine, G | 1 |
| Frank, R | 1 |
| Tonet, JL | 1 |
| Pratt, CM | 6 |
| Luck, JC | 1 |
| Mann, DE | 1 |
| Wyndham, CR | 1 |
| Vanhaleweyk, G | 2 |
| Balakumaran, K | 2 |
| Lubsen, J | 2 |
| ten Cate, FJ | 1 |
| Jovanovic, A | 1 |
| Hagemeijer, F | 1 |
| Withagen, A | 1 |
| Polak, BC | 1 |
| Roelandt, J | 2 |
| Hugenholtz, PG | 2 |
| Aliot, E | 1 |
| Baille, N | 1 |
| Zannad, F | 1 |
| Gilgenkrantz, JM | 1 |
| Banim, SO | 1 |
| Spurrell, RA | 3 |
| Spivack, C | 1 |
| Gottlieb, S | 2 |
| Miura, DS | 1 |
| Somberg, JC | 3 |
| Gentzkow, GD | 2 |
| Sullivan, JY | 1 |
| Kvam, DC | 2 |
| Siddoway, LA | 2 |
| Morganroth, J | 8 |
| Horowitz, LN | 2 |
| Meinertz, T | 2 |
| Zehender, MK | 2 |
| Geibel, A | 2 |
| Treese, N | 3 |
| Hofmann, T | 2 |
| Kasper, W | 2 |
| Pop, T | 3 |
| Abitbol, H | 1 |
| Califano, JE | 1 |
| Abate, C | 1 |
| Beilis, P | 1 |
| Castellanos, H | 1 |
| Perry, BA | 1 |
| Van Hamersveld, DD | 1 |
| Johnson, TA | 1 |
| Conard, GJ | 4 |
| Chang, SF | 1 |
| Pitt, B | 1 |
| Haugland, JM | 1 |
| Asinger, RW | 1 |
| Mikell, FL | 1 |
| Krejci, J | 2 |
| Thale, J | 3 |
| Gülker, H | 3 |
| Bender, F | 3 |
| Heuer, H | 3 |
| Duran, D | 1 |
| Platia, EV | 2 |
| Griffith, LS | 1 |
| Adhar, G | 1 |
| Reid, PR | 1 |
| Brisse, B | 1 |
| Kristek, J | 2 |
| Schindelhauer, F | 2 |
| Teerling, K | 1 |
| Hübner, G | 1 |
| Olsson, SB | 1 |
| Edvardsson, N | 1 |
| Maffucci, RJ | 1 |
| Vesper, BS | 1 |
| Higgins, SB | 1 |
| Smith, RF | 1 |
| Somani, P | 1 |
| Haruno, A | 1 |
| Hashimoto, K | 3 |
| Rouet, R | 1 |
| Ducouret, P | 1 |
| Hallstrom, AP | 4 |
| Carlson, M | 1 |
| Davies, R | 1 |
| Greene, HL | 6 |
| Kammerling, JM | 1 |
| Romhilt, DW | 2 |
| Huther, M | 2 |
| Kidwell, GA | 1 |
| Gonzalez, MD | 1 |
| Coromilas, J | 1 |
| Saltman, AE | 1 |
| Waldecker, B | 1 |
| Dillon, SM | 1 |
| Wit, AL | 1 |
| Hallstrom, A | 3 |
| DeMaria, A | 1 |
| Young, JB | 1 |
| Takanaka, C | 1 |
| Lee, JK | 1 |
| Nonokawa, M | 1 |
| Sugiyama, T | 1 |
| Yame, S | 1 |
| Restivo, M | 1 |
| Yin, H | 1 |
| Caref, EB | 1 |
| Patel, AI | 1 |
| Ndrepepa, G | 1 |
| Avitable, MJ | 1 |
| Assadi, MA | 1 |
| Isber, N | 1 |
| el-Sherif, N | 2 |
| Henthorn, RW | 2 |
| Buckingham, TA | 1 |
| Carlson, MD | 1 |
| Carson, PE | 1 |
| Auricchio, A | 1 |
| Auricchio, U | 1 |
| Chiariello, L | 1 |
| Boriani, G | 2 |
| Capucci, A | 3 |
| Strocchi, E | 2 |
| Calliva, R | 2 |
| Santarelli, A | 1 |
| Biffi, M | 1 |
| Magnani, B | 2 |
| Barranco, F | 1 |
| Sanchez, M | 1 |
| Rodriguez, J | 1 |
| Guerrero, M | 1 |
| Epstein, AE | 2 |
| Rogers, WJ | 1 |
| Liebson, PR | 3 |
| Seals, AA | 1 |
| Cohen, JD | 2 |
| Capone, RJ | 2 |
| Wyse, DG | 3 |
| Ogawa, S | 2 |
| Mitamura, H | 1 |
| Katoh, H | 2 |
| Ushinohama, H | 1 |
| Hara, M | 1 |
| Otuka, M | 1 |
| Harada, K | 1 |
| Okuni, M | 1 |
| Peters, RW | 2 |
| Mitchell, LB | 2 |
| Brooks, MM | 3 |
| Echt, DS | 2 |
| Barker, AH | 3 |
| Capone, R | 1 |
| Aupetit, JF | 2 |
| Timour, Q | 2 |
| Larbre, JP | 2 |
| Loufoua-Moundanga, J | 2 |
| Kioueh, I | 1 |
| Lopez, M | 1 |
| Faucon, G | 2 |
| Sumikawa, K | 1 |
| Kawabata, K | 1 |
| Yoshiya, I | 1 |
| Krishnan, SC | 2 |
| Müller, A | 1 |
| Gerwin, R | 1 |
| Klaus, W | 1 |
| Gorkin, L | 1 |
| Schron, EB | 1 |
| Wiklund, I | 1 |
| Kellen, J | 1 |
| Verter, J | 1 |
| Schoenberger, JA | 1 |
| Pawitan, Y | 3 |
| Morris, M | 2 |
| Shumaker, S | 1 |
| Sopher, SM | 1 |
| Hopson, JR | 1 |
| Buxton, AE | 1 |
| Rinkenberger, RL | 3 |
| Heilman, JM | 1 |
| Kienzle, MG | 1 |
| Chimienti, M | 1 |
| Cullen, MT | 1 |
| Casadei, G | 1 |
| Obias-Manno, D | 2 |
| Friedmann, E | 1 |
| Thomas, SA | 1 |
| Haakenson, C | 1 |
| Wimbush, F | 1 |
| Somelofski, C | 1 |
| Goldner, F | 1 |
| Paperini, L | 1 |
| Davini, A | 1 |
| Lattanzi, F | 1 |
| Topi, A | 1 |
| Reisenhofer, B | 1 |
| Squarcini, G | 1 |
| Paci, A | 1 |
| Topi, PL | 1 |
| Heisler, BE | 1 |
| Ferrier, GR | 1 |
| Arnsdorf, MF | 1 |
| Sawicki, GJ | 1 |
| Packer, DL | 1 |
| Munger, TM | 1 |
| Johnson, SB | 1 |
| Cragun, KT | 1 |
| Thomas, O | 1 |
| Nakazato, Y | 2 |
| Nakata, Y | 2 |
| Yasuda, M | 2 |
| Nakazato, K | 2 |
| Sumiyoshi, M | 2 |
| Ogura, S | 1 |
| Yamaguchi, H | 1 |
| Josephson, ME | 1 |
| Xue, YX | 1 |
| Arita, J | 1 |
| Aye, NN | 1 |
| Villani, GQ | 1 |
| Piepoli, MF | 1 |
| Aschieri, D | 1 |
| Tachibana, H | 3 |
| Yamaki, M | 3 |
| Kubota, I | 3 |
| Watanabe, T | 3 |
| Yamauchi, S | 2 |
| Tomoike, H | 3 |
| Naccarelli, GV | 2 |
| Dougherty, AH | 3 |
| Wolbrette, D | 1 |
| Wiggins, S | 1 |
| Yue, L | 1 |
| Feng, JL | 1 |
| Wang, Z | 1 |
| Nattel, S | 2 |
| Devos, D | 1 |
| Defebvre, L | 1 |
| Destée, A | 1 |
| Caron, J | 1 |
| Yamashita, H | 1 |
| Sekita, G | 1 |
| Kawano, Y | 1 |
| Mineda, Y | 1 |
| Tokano, T | 1 |
| Vautier-Rit, S | 1 |
| Dufour, P | 1 |
| Vaksmann, G | 1 |
| Subtil, D | 1 |
| Vaast, P | 1 |
| Valat, AS | 1 |
| Dubos, JP | 1 |
| Puech, F | 1 |
| Bezzina, CR | 1 |
| George, AL | 1 |
| Danse, PW | 1 |
| Garratt, CJ | 1 |
| Allessie, MA | 1 |
| Liu, H | 1 |
| Tateyama, M | 1 |
| Abriel, H | 1 |
| Tonkin, AM | 1 |
| Nesterenko, VV | 1 |
| Lastra, AA | 1 |
| Rosenshtraukh, LV | 1 |
| Starmer, CF | 1 |
| Hohnloser, SH | 1 |
| Zabel, M | 1 |
| Brakhmann, I | 1 |
| Shmitt, K | 1 |
| Baĭer, T | 1 |
| Valdeker, B | 1 |
| Khilbel, T | 1 |
| Kiubler, V | 1 |
| Perry, JC | 3 |
| Garson, A | 3 |
| Vaughan Williams, EM | 2 |
| Crozier, I | 1 |
| Donovan, KD | 1 |
| Dobb, GJ | 1 |
| Coombs, LJ | 1 |
| Lee, KY | 1 |
| Weekes, JN | 1 |
| Murdock, CJ | 1 |
| Clarke, GM | 1 |
| Chouty, F | 2 |
| Denjoy, I | 2 |
| Slama, R | 2 |
| Hashimoto, H | 1 |
| Nakashima, M | 1 |
| Katz, RJ | 1 |
| Birgersdotter, UM | 1 |
| Wong, W | 1 |
| Turgeon, J | 1 |
| Akiyama, T | 1 |
| Campbell, WB | 1 |
| Papa, L | 1 |
| Rubbert, P | 1 |
| Friedman, L | 2 |
| Keller, M | 1 |
| Josephson, RA | 1 |
| Vincenti, A | 1 |
| Landolina, M | 1 |
| Latini, R | 3 |
| Cavalli, A | 2 |
| Giani, P | 1 |
| Hanston, P | 1 |
| Evrard, P | 1 |
| Mahieu, P | 1 |
| Wallemacq, P | 1 |
| Friob, M | 1 |
| Hassoun, A | 1 |
| Brater, DC | 1 |
| Harrell, FE | 1 |
| Kowey, PR | 1 |
| Leier, CV | 1 |
| Lowenthal, DT | 1 |
| Messerli, F | 1 |
| Packer, M | 1 |
| Pritchett, EL | 2 |
| Ruskin, JN | 2 |
| Akhtar, M | 1 |
| Janse, MJ | 1 |
| Lazzara, R | 1 |
| Myerburg, RJ | 1 |
| Schwartz, PJ | 5 |
| Waldo, AL | 2 |
| Wellens, HJ | 1 |
| Strasberg, B | 2 |
| Stein, S | 1 |
| Sclarovsky, S | 1 |
| Prystowsky, EN | 1 |
| Katz, A | 1 |
| Knilans, TK | 1 |
| Gloor, HO | 1 |
| Frame, LH | 1 |
| Rhee, EK | 1 |
| Fei, H | 1 |
| Luchetti, W | 1 |
| Somberg, J | 3 |
| Brugada, J | 2 |
| Boersma, L | 2 |
| Kirchhof, C | 2 |
| Allessie, M | 2 |
| Kerin, NZ | 1 |
| Frabetti, L | 1 |
| Ambrosioni, E | 1 |
| Yorikane, R | 1 |
| Mizuno, H | 1 |
| Itoh, Y | 1 |
| Koike, H | 1 |
| Miyake, S | 1 |
| Shiga, H | 1 |
| Kumakura, S | 1 |
| Fukami, M | 1 |
| Shimoji, Y | 1 |
| Hashimoto, T | 1 |
| Winslow, E | 1 |
| Campbell, JK | 1 |
| Barron, E | 1 |
| Marshall, RJ | 1 |
| Muir, AW | 1 |
| Zuanetti, G | 2 |
| Neilson, JM | 1 |
| Ewing, DJ | 1 |
| Arensberg, D | 1 |
| Baker, A | 1 |
| Wilkinson, WE | 1 |
| Borgeat, A | 2 |
| Petropoulos, P | 1 |
| Cavin, R | 1 |
| Biollaz, J | 2 |
| Munafo, A | 1 |
| Schwander, D | 1 |
| Bigger, JT | 4 |
| Reynolds-Haertle, RA | 1 |
| McBride, R | 1 |
| Steinberg, JS | 1 |
| Mahmarian, J | 1 |
| Gillette, PC | 2 |
| Benson, DW | 1 |
| Gerentes-Chassagne, I | 1 |
| Geraci, TS | 1 |
| Handshaw, K | 1 |
| Schlant, RC | 1 |
| Huther, ML | 1 |
| Moye, LA | 1 |
| Sihm, I | 1 |
| Hansen, FA | 1 |
| Rasmussen, J | 1 |
| Pedersen, AK | 1 |
| Thygesen, K | 1 |
| Metz, D | 1 |
| Chapoutot, L | 1 |
| Laudinat, JM | 1 |
| Ehrhard, V | 1 |
| Taupin, JM | 1 |
| Chabert, JP | 1 |
| Metivet, F | 1 |
| Pollet, E | 1 |
| Bajolet, A | 1 |
| Furlanello, F | 2 |
| Sakurada, H | 1 |
| Hiyoshi, Y | 1 |
| Tejima, T | 1 |
| Yanase, O | 1 |
| Tokuyasu, Y | 1 |
| Watanabe, K | 1 |
| Motomiya, T | 1 |
| Sugiura, M | 1 |
| Hiraoka, M | 1 |
| Kennedy, HL | 1 |
| Herre, JM | 1 |
| Titus, C | 1 |
| Eldar, M | 1 |
| Franz, MR | 1 |
| Griffin, JC | 1 |
| Scheinman, MM | 1 |
| Sagie, A | 1 |
| Reiffel, JA | 1 |
| Cook, JR | 1 |
| Case, CL | 1 |
| Moye, L | 1 |
| Bashir, Y | 1 |
| Turakhia, DP | 1 |
| Warren, R | 1 |
| Vohra, J | 1 |
| Hunt, D | 1 |
| Hamer, A | 1 |
| Gagnol, JP | 1 |
| Bayés de Luna, A | 1 |
| Guindo, J | 1 |
| Borja, J | 1 |
| Roman, M | 1 |
| Madoery, C | 1 |
| Mentré, F | 1 |
| Papouchado, M | 1 |
| James, MA | 1 |
| Clarke, LM | 1 |
| Miura, D | 2 |
| Keefe, DL | 1 |
| Nestico, PF | 3 |
| Matsuo, S | 1 |
| Koh, Y | 1 |
| Sato, R | 1 |
| Munakata, K | 1 |
| Kishida, H | 1 |
| Polizzi, CA | 1 |
| Carelli, M | 1 |
| Giampaolo, P | 1 |
| Di Marcotullio, G | 1 |
| Tubaro, M | 1 |
| Malinconico, U | 1 |
| Milazzotto, F | 1 |
| Wafa, SS | 1 |
| Ward, DE | 3 |
| Parker, DJ | 1 |
| Liem, LB | 1 |
| Kates, RE | 1 |
| Skluth, H | 1 |
| Grauer, K | 1 |
| Gums, J | 1 |
| Clyburn, PA | 1 |
| Fassoulaki, A | 1 |
| Rosen, M | 1 |
| Webster, J | 1 |
| Nightingale, SL | 1 |
| Saini, V | 1 |
| Podrid, PJ | 4 |
| Slater, W | 1 |
| Lown, B | 1 |
| Facchini, M | 3 |
| Varisco, T | 3 |
| Bonazzi, O | 3 |
| Songa, V | 1 |
| Abi Samra, F | 1 |
| McQuinn, RL | 1 |
| Smith, RT | 1 |
| Gothing, C | 1 |
| Fredell, P | 1 |
| Sugiyama, S | 1 |
| Hieda, N | 1 |
| Ozawa, T | 1 |
| Fukushima, A | 1 |
| Ogawa, T | 1 |
| Hanaki, Y | 1 |
| Coyle, JD | 1 |
| Schaal, SF | 1 |
| Cordoni, M | 1 |
| Scalzini, A | 1 |
| Bechi, S | 1 |
| Franchini, C | 1 |
| Mazza, F | 1 |
| Micheli, G | 1 |
| Bayer-Berger, M | 1 |
| Kappenberger, L | 1 |
| Chapuis, G | 1 |
| Chioléro, R | 1 |
| Wu, KM | 1 |
| Hunter, T | 1 |
| Proakis, A | 1 |
| Maloney, JD | 1 |
| Akiyama, K | 1 |
| Gottlieb, SS | 1 |
| Marcus, FI | 2 |
| Kieny, JR | 1 |
| Kraenner, C | 1 |
| Facello, A | 1 |
| Roul, G | 1 |
| Mossard, JM | 1 |
| Bareiss, P | 1 |
| Sacrez, A | 1 |
| Garratt, C | 1 |
| Van Gelder, IC | 1 |
| Crijns, HJ | 1 |
| Van Gilst, WH | 1 |
| Van Wijk, LM | 2 |
| Hamer, HP | 1 |
| Lie, KI | 2 |
| Sakai, T | 1 |
| Hosokawa, M | 1 |
| Miyazaki, T | 1 |
| Sakurai, K | 1 |
| Nakamura, Y | 1 |
| Tognarini, S | 1 |
| Pardini, E | 1 |
| Gallicchio, F | 1 |
| Aragona, PL | 1 |
| Chiatto, M | 1 |
| Pugliese, F | 1 |
| Donnangelo, L | 1 |
| Ranger, S | 1 |
| Talajic, M | 1 |
| Lemery, R | 1 |
| Roy, D | 1 |
| Keyler, DE | 1 |
| Pentel, PR | 1 |
| Jones, K | 1 |
| Wood, SM | 1 |
| Kelliher, GJ | 1 |
| Kowey, P | 1 |
| Engel, T | 1 |
| Wetstein, L | 1 |
| Mancuso, G | 1 |
| Tampieri, E | 1 |
| Berdondini, RM | 1 |
| Frabetti, F | 1 |
| Dattola, L | 1 |
| Bellodi, G | 1 |
| Padovani, F | 1 |
| Huang, SK | 1 |
| Tepper, D | 1 |
| Ramhamadany, E | 1 |
| Mackenzie, S | 1 |
| Ramsdale, DR | 1 |
| Till, JA | 1 |
| Rowland, E | 1 |
| Shinebourne, EA | 1 |
| Vergara, G | 1 |
| Bettini, R | 1 |
| Mosna, G | 1 |
| Gramegna, L | 1 |
| Disertori, M | 1 |
| Berns, E | 1 |
| Jeang, MK | 1 |
| Jenkins, M | 1 |
| Ong, ML | 1 |
| Jackson, G | 1 |
| Johnston, A | 1 |
| Bhamra, R | 1 |
| Holt, DW | 2 |
| Warin, JF | 1 |
| Benchimol, D | 1 |
| Le Métayer, P | 1 |
| Regaudie, JJ | 1 |
| Blanchot, P | 1 |
| Kling, D | 1 |
| Boldt, J | 1 |
| Russ, W | 1 |
| Görlach, G | 1 |
| Hempelmann, G | 1 |
| Brembilla-Perrot, B | 1 |
| Amor, M | 1 |
| Auque, F | 1 |
| Isaaz, K | 1 |
| Terrier de la Chaise, A | 1 |
| Bertrand, A | 1 |
| Cherrier, F | 1 |
| Pernot, C | 1 |
| Gomoll, AW | 1 |
| Chase, SL | 1 |
| Sloskey, GE | 1 |
| Senior, S | 2 |
| Baessler, C | 1 |
| Monzo, M | 1 |
| Croce, L | 1 |
| Romano, S | 1 |
| Pozzoni, L | 1 |
| Lomuscio, A | 1 |
| Nitsch, J | 1 |
| Köhler, U | 1 |
| Neyses, L | 1 |
| Lüderitz, B | 1 |
| Wang, T | 1 |
| Thompson, KA | 1 |
| Bergstrand, RH | 1 |
| Kvam, D | 1 |
| Maggioni, AP | 1 |
| Marchi, S | 1 |
| Volpi, A | 1 |
| Marwick, TH | 1 |
| Woodhouse, SP | 1 |
| Lanza, GA | 1 |
| Tamburi, S | 1 |
| Mondello Malvestiti, FM | 1 |
| Rebuzzi, AG | 1 |
| Lucente, M | 1 |
| Forbes, WP | 1 |
| Hee, TT | 1 |
| Mohiuddin, SM | 1 |
| Hillman, DE | 1 |
| Stoltz, JP | 1 |
| Weingrod, M | 1 |
| Leroy, G | 1 |
| Halphen, C | 1 |
| Haïat, R | 1 |
| Wickers, F | 1 |
| Haissaguere, M | 1 |
| Palussiere, J | 1 |
| Gavaghan, TP | 1 |
| Koegh, AM | 1 |
| Kelly, RP | 1 |
| Campbell, TJ | 1 |
| Thorburn, C | 1 |
| Morgan, JJ | 1 |
| Priestley, KA | 1 |
| Ladusans, EJ | 1 |
| Tynan, MJ | 1 |
| Jones, OD | 1 |
| Curry, PV | 1 |
| Zha, YM | 1 |
| Rewerski, W | 1 |
| Walczak, F | 1 |
| Nyznyk, M | 1 |
| Dorociak, A | 1 |
| Skorupska, U | 1 |
| Mueller, RA | 1 |
| Baur, HR | 1 |
| Grubb, BP | 1 |
| Tilley-Gray, B | 1 |
| Webb, CR | 1 |
| Spielman, SR | 1 |
| Greenspan, AM | 1 |
| Larson, T | 1 |
| Erlien, D | 1 |
| Berry, D | 1 |
| Pepper, GA | 1 |
| Holmes, B | 1 |
| Heel, RC | 1 |
| Dubner, SJ | 1 |
| Elencwajg, BD | 1 |
| Palma, S | 1 |
| Mendelzon, R | 1 |
| Ramos, A | 1 |
| Bertolasi, CA | 1 |
| Smith, GH | 1 |
| Lal, R | 2 |
| Chapman, PD | 1 |
| Naccarrelli, GV | 1 |
| Troup, PJ | 1 |
| Ruffy, R | 2 |
| Wynn, J | 1 |
| Torres, V | 1 |
| Flowers, D | 1 |
| Mizruchi, M | 1 |
| Keefe, D | 1 |
| Shea, P | 1 |
| Schechtman, K | 1 |
| Davis, LD | 1 |
| Hauswirth, O | 1 |
| Wehr, M | 1 |
| Noll, B | 1 |
| Krappe, J | 1 |
| Dunselman, PH | 1 |
| Kingma, JH | 1 |
| Dijk, A | 1 |
| Wesseling, H | 1 |
| Stern, H | 1 |
| Scheininger, M | 1 |
| Theisen, F | 1 |
| Theisen, K | 1 |
| Cuspidi, C | 1 |
| Priori, S | 1 |
| Raviele, A | 1 |
| Piccolo, E | 1 |
| Goy, JJ | 1 |
| Grbic, M | 1 |
| Hurni, M | 1 |
| Finci, L | 1 |
| Maendly, R | 1 |
| Duc, J | 1 |
| Sigwart, U | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Determining the Effects of Two Different Anesthesia Induction Techniques on QT Distance in Cardiac Surgery Patients With Two Different QT Measurement Techniques[NCT04706104] | 60 participants (Actual) | Observational | 2020-10-10 | Completed | |||
| A Prospective Randomized Crossover Trial of Oral Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia[NCT01117454] | 14 participants (Actual) | Interventional | 2011-12-31 | Completed | |||
| The EU TrigTreat Clinical Study: An Advanced Diagnostics and Observational Trial for Arrhythmia Risk Stratification and Correlation With Genotype[NCT01209494] | 672 participants (Actual) | Observational | 2010-01-31 | Completed | |||
| [NCT00000526] | Phase 3 | 0 participants | Interventional | 1986-08-31 | Completed | ||
| Acute Mechanical Response to Anti-arrhythmic Drug Therapy[NCT02575534] | 0 participants (Actual) | Interventional | 2015-10-31 | Withdrawn (stopped due to No enrollment in study.) | |||
| Catheter Ablation for Ventricular Tachycardia in Patients With an Implantable Cardioverter Defibrillator (CALYPSO) PILOT TRIAL[NCT01576042] | 27 participants (Actual) | Interventional | 2012-05-31 | Terminated (stopped due to Main objectives of the study were met; consensus among investigators that continuing the study would not add new information beyond that already learned.) | |||
| Can Global Peak Longitudinal Strain Measurements in Combination With Non-invasive ECG Parameters Predict the Success or Failure of Flecainide Treatment for Atrial Fibrillation Patients?[NCT05084495] | 100 participants (Anticipated) | Observational | 2022-02-01 | Recruiting | |||
| [NCT00000504] | Phase 2 | 0 participants | Interventional | 1982-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Hypothesis: the addition of oral flecainide to standard therapy will reduce ventricular ectopy and/or VT on treadmill exercise treadmill testing in patients with CPVT, compared to placebo plus standard therapy. (NCT01117454)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Flecainide | 2 |
| Placebo | 9 |
Records participants hospitalized for VT during the study (NCT01576042)
Timeframe: Baseline, 6 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 5 |
| Antiarrhythmic Medication | 7 |
Records participants who completed Month 3 Follow-Up Visit (NCT01576042)
Timeframe: 3 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 11 |
| Antiarrhythmic Medication | 12 |
Records participants who completed Month 6 Follow-Up Visit (NCT01576042)
Timeframe: 6 Months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 7 |
| Antiarrhythmic Medication | 10 |
Records participants who had at least one of the efficacy outcome measurement (including death, hospitalization due to VT) (NCT01576042)
Timeframe: 6 Months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 11 |
| Antiarrhythmic Medication | 14 |
Records participants who received study randomized treatment during the study (NCT01576042)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 11 |
| Antiarrhythmic Medication | 14 |
Records participants who only received study treatment as randomized during the entire study (NCT01576042)
Timeframe: 6 month
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 6 |
| Antiarrhythmic Medication | 13 |
Records participants who received study treatment as randomized and later switched to other treatment arm during the study (NCT01576042)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 5 |
| Antiarrhythmic Medication | 1 |
Days from the date of the first study treatment to the date of first ICD recurrent therapy for VT. (NCT01576042)
Timeframe: Baseline, 6 months
| Intervention | Days (Mean) |
|---|---|
| Catheter Ablation | 70.1 |
| Antiarrhythmic Medication | 78.7 |
52 reviews available for flecainide and Arrhythmias, Cardiac
| Article | Year |
|---|---|
Atrial Flutter in Pediatric Patients.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Flutter; Child; Child, Preschool; D | 2022 |
First-Line Antiarrhythmic Transplacental Treatment for Fetal Tachyarrhythmia: A Systematic Review and Meta-Analysis.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Echocardiography; Female; Fetal Diseases; Fetal Therap | 2017 |
Intravenous Flecainide for Emergency Department Management of Acute Atrial Fibrillation.
Topics: Administration, Intravenous; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Elec | 2018 |
Flecainide acetate for the treatment of atrial and ventricular arrhythmias.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Flecainide; Humans; Prac | 2013 |
Meta-analysis of flecainide safety in patients with supraventricular arrhythmias.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiomegaly; Female; Flecainide; Heart V | 2002 |
An avoidable antiarrhythmic side effect.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Catheter Ablation; E | 2006 |
Quinidine in short QT syndrome: an old drug for a new disease.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disease Models, Animal; Electrocardiography; | 2007 |
A proposal for the clinical use of flecainide.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocardiography; Flecainide; Hemodynamics; Humans; | 1984 |
The electrophysiology and pharmacology of verapamil, flecainide, and amiodarone: correlations with clinical effects and antiarrhythmic actions.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzofurans; Drug Interactions; F | 1984 |
Therapy with investigational antiarrhythmic drugs.
Topics: Amiodarone; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzeneacetamides; Encainide; Fl | 1984 |
Comparison of the efficacy of newly developed antiarrhythmic drugs in the treatment of ventricular tachyarrhythmias.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzeneacetamides; Coronary Disease; Encaini | 1984 |
Investigational antiarrhythmic drugs for the treatment of ventricular rhythm disturbances.
Topics: Amiodarone; Anilides; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Encainide; Flecainide | 1984 |
Atrial fibrillation: maintenance of sinus rhythm versus rate control.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Calc | 1996 |
[Propafenone and flecainide in the therapy of ventricular arrhythmias].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiovascular Diseases; Drug Evaluation; | 1995 |
Mechanism of lethal proarrhythmia observed in the Cardiac Arrhythmia Suppression Trial: role of adrenergic modulation of drug binding.
Topics: Animals; Arrhythmias, Cardiac; Flecainide; Heart Conduction System; Humans; Myocardial Infarction | 1997 |
[Pharmacological treatment of atrial fibrillation].
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibril | 1997 |
The role of oral 1C antiarrhythmic drugs in terminating atrial fibrillation.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Flecainide; | 1999 |
Treatment of ventricular arrhythmias after CAST.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical Trials as Topic | 1992 |
Short- and long-term efficacy and safety of flecainide acetate for supraventricular arrhythmias.
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Flecainide; Humans; Meta-Analysis as Topi | 1992 |
Flecainide acetate for treatment of tachyarrhythmias in children: review of world literature on efficacy, safety, and dosing.
Topics: Arrhythmias, Cardiac; Child; Child, Preschool; Fetal Diseases; Flecainide; Humans; Infant; Tachycard | 1992 |
Classifying antiarrhythmic actions: by facts or speculation.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Encainide; Flecaini | 1992 |
Flecainide in the Wolff-Parkinson-White syndrome.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Flecainide; Heart Conduction Syst | 1992 |
CAST and beyond. Implications of the Cardiac Arrhythmia Suppression Trial. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Double-Blind M | 1990 |
Ventricular arrhythmias: risk stratification and approach to therapy after the Cardiac Arrhythmia Suppression Trial (CAST).
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Encainide; Flecainide; Heart Ventricles; Hum | 1990 |
[What is the latest in anti-arrhythmia therapy?].
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical Tri | 1991 |
Significance of classifying antiarrhythmic actions since the cardiac arrhythmia suppression trial.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Electrocardiograph | 1991 |
The Cardiac Arrhythmia Suppression Trial: background, interim results and implications.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Encainide; Flecainide; Humans; Myocardial In | 1990 |
Clinical implications of new studies in the treatment of benign, potentially malignant and malignant ventricular arrhythmias.
Topics: Amiodarone; Anilides; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Encainide; Flecainide; | 1990 |
Comparisons of efficacy and tolerance of moricizine with other antiarrhythmic agents in the treatment of chronic ventricular arrhythmias.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disopyramide; Double-Blind Method; Encainide | 1990 |
[Comparative study of cibenzoline and flecainide administered via an intravenous route in reducing auricular arrhythmia].
Topics: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Flecainide; Hu | 1990 |
[Class Ic antiarrhythmic drugs--flecainide and propafenone].
Topics: Arrhythmias, Cardiac; Flecainide; Humans; Propafenone | 1990 |
Reassessment of benefit-risk ratio and treatment algorithms for antiarrhythmic drug therapy after the cardiac arrhythmia suppression trial.
Topics: Algorithms; Anilides; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topi | 1990 |
Class IC drugs: propafenone and flecainide.
Topics: Arrhythmias, Cardiac; Flecainide; Humans; Propafenone | 1990 |
The treatment of ventricular rhythm disturbances.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premat | 1986 |
Update: cardiac antiarrhythmic drugs.
Topics: Amiodarone; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzeneacetamides; Encainide; Fl | 1989 |
Ventricular arrhythmias. An assessment of newer therapeutic agents.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Flecainide; Humans; Lidocaine; Mexiletine; | 1989 |
The clinical use of class IC antiarrhythmic drugs.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Encainide; Flecainide; Humans; Propafenone | 1989 |
Antiarrhythmic drug therapy. Recent advances and current status.
Topics: Adrenergic beta-Antagonists; Ajmaline; Amiodarone; Anilides; Anti-Arrhythmia Agents; Aprindine; Arrh | 1985 |
Clinical pharmacology of antiarrhythmic agents.
Topics: Adrenergic beta-Antagonists; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzeneacetamid | 1985 |
Cardiac arrhythmias in the elderly: antiarrhythmic drug treatment.
Topics: Aged; Amiodarone; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Bretylium Compounds; Digox | 1986 |
Antiarrhythmic drug therapy of ventricular arrhythmias.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Bretylium Tosylate; Disopyramide; Flecaini | 1986 |
Antiarrhythmic agents for chronic ventricular arrhythmias.
Topics: Amiodarone; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disopyramide; Encainide; Flecain | 1987 |
Flecainide and encainide.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Encainide; Flecainide; Humans | 1987 |
Encainide hydrochloride and flecainide acetate: two class 1c antiarrhythmic agents.
Topics: Anilides; Arrhythmias, Cardiac; Drug Interactions; Encainide; Flecainide; Humans | 1987 |
Flecainide acetate: critical care administration guidelines.
Topics: Arrhythmias, Cardiac; Critical Care; Electrocardiography; Flecainide; Humans; Monitoring, Physiologi | 1988 |
[Flecainide and anti-arrhythmia therapy].
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Electrocardiography; Flecainide; Heart Ventricles; Humans | 1988 |
Flecainide: a new antiarrhythmic drug.
Topics: Action Potentials; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrophysiology; Flecainide; Hemo | 1986 |
Drug therapy. Flecainide.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Drug Interactions; Electrocardiography; Fleca | 1986 |
Flecainide: a new agent for the treatment of ventricular arrhythmias.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocardiography; Flecainide; Heart Ventricles; Hum | 1986 |
Flecainide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Biotransformation; Drug Interactions; Electro | 1985 |
Flecainide: a new class Ic antidysrhythmic.
Topics: Action Potentials; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Drug Inte | 1985 |
Antiarrhythmic drug therapy (Part 2). Benefits and hazards.
Topics: Amiodarone; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzeneacetamides; Encainide; Fl | 1985 |
67 trials available for flecainide and Arrhythmias, Cardiac
| Article | Year |
|---|---|
Short QT Syndrome: a familial cause of sudden death.
Topics: Adolescent; Adult; Aged; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiac Complexes, Premature; Ch | 2003 |
Short QT syndrome: pharmacological treatment.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Child; Death, Sudden, Cardiac | 2004 |
Assessment of serum flecainide trough levels in patients with tachyarrhythmia.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chromatography, High Pressure Liquid; Dose-Response Re | 2005 |
Selection of an antiarrhythmic drug for a sudden-death-prevention trial.
Topics: Acecainide; Amiodarone; Anilides; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Benzeneac | 1982 |
Flecainide versus quinidine for treatment of chronic ventricular arrhythmias. A multicenter clinical trial.
Topics: Administration, Oral; Adult; Aged; Arrhythmias, Cardiac; Clinical Trials as Topic; Double-Blind Meth | 1983 |
Comparison of flecainide with quinidine for suppression of chronic stable ventricular ectopic depolarizations. A double-blind randomized study in ambulatory outpatients.
Topics: Adult; Aged; Ambulatory Care; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic | 1983 |
Discovery and development of flecainide.
Topics: Anesthetics, Local; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Drug Eva | 1984 |
Flecainide versus quinidine: results of a multicenter trial.
Topics: Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Electrocardiography; | 1984 |
Efficacy and tolerance of intravenous flecainide in patients with chronic high frequency ventricular arrhythmias.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Blood Pressure; Clinical Trials as Topic; | 1984 |
[Flecainide: a new antiarrhythmic agent].
Topics: Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Drug Tolerance; Elect | 1983 |
Oral flecainide acetate for the treatment of ventricular arrhythmias.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as | 1981 |
Suppression of ventricular ectopic depolarizations by flecainide acetate, a new antiarrhythmic agent.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocardiography; Female; Flecainide; Humans; | 1982 |
Suppression of complex ventricular arrhythmias by oral flecainide.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Blood Pressure; Dru | 1982 |
Time to arrhythmic, ischemic, and heart failure events: exploratory analyses to elucidate mechanisms of adverse drug effects in the Cardiac Arrhythmia Suppression Trial.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Double-Blind Method; Encainide; Flecainide; Heart Fail | 1995 |
Relations between heart failure, ejection fraction, arrhythmia suppression and mortality: analysis of the Cardiac Arrhythmia Suppression Trial.
Topics: Arrhythmias, Cardiac; Electrocardiography; Encainide; Female; Flecainide; Heart Failure; Humans; Mal | 1995 |
Interaction of baseline characteristics with the hazard of encainide, flecainide, and moricizine therapy in patients with myocardial infarction. A possible explanation for increased mortality in the Cardiac Arrhythmia Suppression Trial (CAST).
Topics: Arrhythmias, Cardiac; Encainide; Female; Flecainide; Humans; Male; Middle Aged; Moricizine; Myocardi | 1994 |
Partial reversal by exercise of protective effect in atrial fibrillation inducibility in patients with an accessory atrioventricular connection: comparison between flecainide and propafenone.
Topics: Adult; Arrhythmias, Cardiac; Electric Stimulation; Exercise Test; Female; Flecainide; Humans; Male; | 1994 |
Efficacy of flecainide in patients with supraventricular arrhythmias and respiratory insufficiency.
Topics: Acute Disease; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Chi-Square Distribution; Electrocardio | 1994 |
Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction. The original design concept of the Cardiac Arrhythmia Suppression Trial (CAST).
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Encainide; Female; Flecainide; Humans; Male; Mid | 1993 |
Circadian pattern of arrhythmic death in patients receiving encainide, flecainide or moricizine in the Cardiac Arrhythmia Suppression Trial (CAST).
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Aspirin; Circadian Rhythm; Death, Sudden, Cardia | 1994 |
Psychosocial predictors of mortality in the Cardiac Arrhythmia Suppression Trial-1 (CAST-1).
Topics: Arrhythmias, Cardiac; Chi-Square Distribution; Encainide; Flecainide; Humans; Moricizine; Myocardial | 1993 |
Safety and utility of flecainide acetate in the routine care of patients with supraventricular tachyarrhythmias: results of a multicenter trial. The Flecainide Supraventricular Tachycardia Study Group.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Arrhythmia | 1996 |
Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Dose-Res | 1995 |
Adherence and arrhythmic mortality in the cardiac arrhythmia suppression trial (CAST).
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Encainide; Female; Flecainide; Health Behavior; Humans | 1996 |
[Propafenone and flecainide in the therapy of ventricular arrhythmias].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiovascular Diseases; Drug Evaluation; | 1995 |
Efficacy of flecainide for the reversion of acute onset atrial fibrillation.
Topics: Acute Disease; Arrhythmias, Cardiac; Atrial Fibrillation; Digoxin; Double-Blind Method; Drug Evaluat | 1992 |
The Cardiac Arrhythmia Suppression Trial: first CAST ... then CAST-II.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Double-Blind Method; Encainide; Flecainide; Humans; Mo | 1992 |
Effects of advancing age on the efficacy and side effects of antiarrhythmic drugs in post-myocardial infarction patients with ventricular arrhythmias. The CAST Investigators.
Topics: Adult; Age Factors; Aged; Aging; Arrhythmias, Cardiac; Drug Therapy, Combination; Encainide; Flecain | 1992 |
Washout of long-term treatment with flecainide and propafenone in patients with complex ventricular arrhythmias and cardiac disease. Antiarrhythmic Drug Evaluation Group.
Topics: Arrhythmias, Cardiac; Electrocardiography; Flecainide; Heart Diseases; Humans; Male; Middle Aged; Pr | 1992 |
Flecainide in cancer nerve pain.
Topics: Adolescent; Adult; Aged; Arrhythmias, Cardiac; Double-Blind Method; Female; Flecainide; Humans; Male | 1991 |
Clinical and regulatory implications of the Cardiac Arrhythmia Suppression Trial.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Flecainide; Humans; Rand | 1990 |
Proarrhythmic potential of moricizine: strengths and limitations of a data base analysis.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical Trial | 1990 |
CAST and beyond. Implications of the Cardiac Arrhythmia Suppression Trial. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Double-Blind M | 1990 |
Flecainide: evidence of non-linear kinetics.
Topics: Adult; Aged; Arrhythmias, Cardiac; Flecainide; Humans; Middle Aged | 1991 |
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.
Topics: Actuarial Analysis; Anilides; Arrhythmias, Cardiac; Electrocardiography; Encainide; Flecainide; Foll | 1991 |
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.
Topics: Actuarial Analysis; Anilides; Arrhythmias, Cardiac; Electrocardiography; Encainide; Flecainide; Foll | 1991 |
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.
Topics: Actuarial Analysis; Anilides; Arrhythmias, Cardiac; Electrocardiography; Encainide; Flecainide; Foll | 1991 |
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.
Topics: Actuarial Analysis; Anilides; Arrhythmias, Cardiac; Electrocardiography; Encainide; Flecainide; Foll | 1991 |
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.
Topics: Actuarial Analysis; Anilides; Arrhythmias, Cardiac; Electrocardiography; Encainide; Flecainide; Foll | 1991 |
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.
Topics: Actuarial Analysis; Anilides; Arrhythmias, Cardiac; Electrocardiography; Encainide; Flecainide; Foll | 1991 |
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.
Topics: Actuarial Analysis; Anilides; Arrhythmias, Cardiac; Electrocardiography; Encainide; Flecainide; Foll | 1991 |
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.
Topics: Actuarial Analysis; Anilides; Arrhythmias, Cardiac; Electrocardiography; Encainide; Flecainide; Foll | 1991 |
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.
Topics: Actuarial Analysis; Anilides; Arrhythmias, Cardiac; Electrocardiography; Encainide; Flecainide; Foll | 1991 |
Prevention of arrhythmias after noncardiac thoracic operations: flecainide versus digoxin.
Topics: Arrhythmias, Cardiac; Digoxin; Electrocardiography, Ambulatory; Flecainide; Humans; Lung; Postoperat | 1991 |
Events in the Cardiac Arrhythmia Suppression Trial (CAST): mortality in the entire population enrolled.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Double-Blind Method; Encainide; Female; Flec | 1991 |
Events in the Cardiac Arrhythmia Suppression Trial (CAST): mortality in patients surviving open label titration but not randomized to double-blind therapy.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Encainide; Female; Flecainide; Humans; Male; | 1991 |
Events in the cardiac arrhythmia suppression trial: baseline predictors of mortality in placebo-treated patients.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chi-Square Distribution; Double-Blind Method; En | 1991 |
The events surrounding the removal of encainide and flecainide from the Cardiac Arrhythmia Suppression Trial (CAST) and why CAST is continuing with moricizine.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Encainide; Flecainide; Humans; Mass Media; M | 1990 |
The Cardiac Arrhythmia Suppression Trial: background, interim results and implications.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Encainide; Flecainide; Humans; Myocardial In | 1990 |
Implications of the Cardiac Arrhythmia Suppression Trial for antiarrhythmic drug treatment.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Double-Blind Method; Encainide; Europe; Flec | 1990 |
Comparisons of efficacy and tolerance of moricizine with other antiarrhythmic agents in the treatment of chronic ventricular arrhythmias.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disopyramide; Double-Blind Method; Encainide | 1990 |
CAST and beyond. Implications of the cardiac arrhythmia suppression trials. By the Task Force of the Working Group on Arrhythmias of the European Society of Cardiology.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Double-Blind Method; Encainide; Flecainide; | 1990 |
[Cardiac arrhythmia suppression trial (CAST)].
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Death, Sudden; Flecainide; H | 1990 |
Clinical trials of flecainide acetate in the management of supraventricular arrhythmias.
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; Flecainide; Humans; | 1990 |
Recasting the approach to the treatment of potentially malignant ventricular arrhythmias after the CAST study.
Topics: Anilides; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cricetinae; Encainide; Flecainide; | 1990 |
Clinical aspects of trial design: what can we expect from the cardiac arrhythmia suppression trial?
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Electric Stimulati | 1990 |
Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.
Topics: Aged; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical | 1989 |
Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.
Topics: Aged; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical | 1989 |
Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.
Topics: Aged; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical | 1989 |
Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.
Topics: Aged; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical | 1989 |
Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.
Topics: Aged; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical | 1989 |
Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.
Topics: Aged; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical | 1989 |
Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.
Topics: Aged; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical | 1989 |
Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.
Topics: Aged; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical | 1989 |
Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.
Topics: Aged; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical | 1989 |
Efficacy of flecainide acetate for atrial arrhythmias following coronary artery bypass grafting.
Topics: Adult; Aged; Arrhythmias, Cardiac; Coronary Artery Bypass; Digoxin; Drug Therapy, Combination; Femal | 1989 |
Flecainide and cardiac dysrhythmias during dental extraction under anaesthesia.
Topics: Adolescent; Adult; Anesthesia, Dental; Anesthesia, General; Arrhythmias, Cardiac; Clinical Trials as | 1989 |
Encainide and flecainide: are they interchangeable?
Topics: Adolescent; Adult; Aged; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocardiography | 1989 |
An interim perspective on the removal of encainide and flecainide from the cardiac arrhythmia suppression trial.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Encainide; Ethics, | 1989 |
Efficacy and safety of flecainide in patients with stable ventricular ectopic beats. Multicenter trial of the Italian Study Group on the Electrophysiology of Arrhythmias.
Topics: Adolescent; Adult; Aged; Arrhythmias, Cardiac; Clinical Trials as Topic; Female; Flecainide; Heart V | 1989 |
Prevention of arrhythmias by flecainide after noncardiac thoracic surgery.
Topics: Adult; Aged; Arrhythmias, Cardiac; Electrocardiography; Flecainide; Humans; Middle Aged; Monitoring, | 1989 |
Consequences of the Cardiac Arrhythmia Suppression Trial: calamity or clarity?
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Consumer Product S | 1989 |
The use of antiarrhythmic agents in heart failure: implications of CAST.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Encainide; Flecain | 1989 |
Lessons to be learned from the cardiac arrhythmia suppression trial.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Encainide; Flecain | 1989 |
Lessons from the cardiac arrhythmia suppression trial.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Encainide; Flecain | 1989 |
Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutte | 1989 |
Flecainide and CAST.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Drug Evaluation; Encainide; Flecainide; Huma | 1989 |
Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: the CAPS.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Double-Blind Metho | 1988 |
[Hemodynamic effects of the anti-arrhythmia agent flecainide (Tambocor) in coronary surgery patients].
Topics: Arrhythmias, Cardiac; Clinical Trials as Topic; Combined Modality Therapy; Coronary Artery Bypass; C | 1987 |
Effect of flecainide on left ventricular ejection fraction.
Topics: Arrhythmias, Cardiac; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Flecainide | 1987 |
Flecainide compared with a combination of digoxin and disopyramide for acute atrial arrhythmias after cardiopulmonary bypass.
Topics: Acute Disease; Aged; Arrhythmias, Cardiac; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Clin | 1988 |
Efficacy of flecainide in the management of ventricular arrhythmias: comparative study with amiodarone.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzofurans; Clinical Trials | 1985 |
Flecainide: a new class Ic antidysrhythmic.
Topics: Action Potentials; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Drug Inte | 1985 |
237 other studies available for flecainide and Arrhythmias, Cardiac
| Article | Year |
|---|---|
Synthesis and cardiac electrophysiological activity of aryl-substituted derivatives of the class III antiarrhythmic agent sematilide. Potential class I/III agents.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chemical Phenomena; Chemis | 1990 |
4,5-Dihydro-1-phenyl-1H-2,4-benzodiazepines: novel antiarrhythmic agents.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzodiazepines; Cats; Disease Models, Animal | 1993 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant | 2008 |
Favourable outcome for hydrops or cardiac failure associated with fetal tachyarrhythmia: a 20-year review.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cesarean Section; Digoxin; Female; Fetal Diseases; Fle | 2022 |
Provocation Testing and Therapeutic Response in a Newly Described Channelopathy: RyR2 Calcium Release Deficiency Syndrome.
Topics: Animals; Arrhythmias, Cardiac; Calcium; Channelopathies; Death, Sudden, Cardiac; Flecainide; Humans; | 2022 |
A peculiar case of palpitations and syncope.
Topics: Andersen Syndrome; Arrhythmias, Cardiac; Flecainide; Humans; Mutation; Syncope | 2022 |
Flecainide poisoning and prolongation of elimination due to alkalinization.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Drug Overdose; Electrocardiography; Flecainide; Humans | 2022 |
Electrocardiographic marker of the cardiac action potential triangulation induced by antiarrhythmic drugs in perfused guinea-pig heart.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocardiography; Fleca | 2022 |
The G213D variant in Nav1.5 alters sodium current and causes an arrhythmogenic phenotype resulting in a multifocal ectopic Purkinje-related premature contraction phenotype in human-induced pluripotent stem cell-derived cardiomyocytes.
Topics: Action Potentials; Arrhythmias, Cardiac; Flecainide; Humans; Induced Pluripotent Stem Cells; Myocyte | 2022 |
QTc Prolongation in Poison Center Exposures to CredibleMeds List of Substances with "Known Risk of Torsades de Pointes".
Topics: Amitriptyline; Arrhythmias, Cardiac; Diphenhydramine; Electrocardiography; Flecainide; Humans; Long | 2022 |
Functional evaluation of the tachycardia patient-derived iPSC cardiomyocytes carrying a novel pathogenic SCN5A variant.
Topics: Arrhythmias, Cardiac; Flecainide; Humans; Induced Pluripotent Stem Cells; Myocytes, Cardiac; NAV1.5 | 2022 |
Male infant with Noonan syndrome with
Topics: Amiodarone; Arrhythmias, Cardiac; Cardiomyopathy, Hypertrophic; Flecainide; Heart Failure; Humans; I | 2022 |
Flecainide toxicity: ECG changes associated with supratherapeutic levels in milk-fed infants.
Topics: Adult; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Child; Child, Preschool; Electrocardio | 2023 |
Diagnostic evaluation of unexplained ventricular tachyarrhythmias in younger adults.
Topics: Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Flecainide; Heart Arrest; Humans; Retro | 2023 |
Left bundle branch block and severe ventricular dysfunction due to flecainide toxicity: a case report.
Topics: Arrhythmias, Cardiac; Bundle-Branch Block; Flecainide; Humans; Ventricular Dysfunction | 2023 |
Wide complex rhythm in a well neonate: Where are the P waves?
Topics: Arrhythmias, Cardiac; Electrocardiography; Flecainide; Heart Ventricles; Humans; Infant, Newborn; Pr | 2023 |
Flecainide plasma level modifications during ledipasvir/sofosbuvir coadministration in two patients affected by chronic hepatitis C.
Topics: Aged; Anti-Arrhythmia Agents; Antiviral Agents; Arrhythmias, Cardiac; Benzimidazoles; Drug Interacti | 2019 |
"Second line medications" for supraventricular arrhythmias in children: In-hospital efficacy and adverse events during treatment initiation of sotalol and flecainide.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Child; Flecainide; Hospitals; Humans; Sotalol | 2021 |
Flecainide Paradoxically Activates Cardiac Ryanodine Receptor Channels under Low Activity Conditions: A Potential Pro-Arrhythmic Action.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Calcium; Flecainide; Ion Channel Gating; Lipi | 2021 |
Transforming growth factor β receptor inhibition prevents ventricular fibrosis in a mouse model of progressive cardiac conduction disease.
Topics: Age Factors; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzamides; Cardiomyopathies; Co | 2017 |
Magnetocardiographic evaluation of nonarrhythmogenic flecainide-induced electrocardiographic T-wave inversion.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Diagnosis, Differential; Electrocardiography; Fe | 2017 |
The Safety and Effectiveness of Flecainide in Children in the Current Era.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiomyopathies; Child, Preschool; Cohort Studies; Fe | 2017 |
Arrhythmogenic drugs can amplify spatial heterogeneities in the electrical restitution in perfused guinea-pig heart: An evidence from assessments of monophasic action potential durations and JT intervals.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrophysiological Pheno | 2018 |
Inhibition of Voltage-Gated K
Topics: Amino Acid Sequence; Anisoles; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Binding Sites; Crystall | 2018 |
Evaluation of cardiac arrhythmic risks using a rabbit model of left ventricular systolic dysfunction.
Topics: Animals; Arrhythmias, Cardiac; Disease Models, Animal; Electrocardiography; Flecainide; Magnetic Res | 2018 |
Acute isoproterenol leads to age-dependent arrhythmogenesis in guinea pigs.
Topics: Action Potentials; Age Factors; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden | 2018 |
Digitalis Promotes Ventricular Arrhythmias in Flecainide- and Ranolazine-Pretreated Hearts.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiotoxicity; Digitalis | 2019 |
Action potential wavelength restitution predicts alternans and arrhythmia in murine Scn5a(+/-) hearts.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Flecainide; Heart | 2013 |
Combined inhibition of Na⁺ and Ca²⁺ channels: a novel paradigm for the treatment of incessant ventricular arrhythmias in Andersen-Tawil syndrome.
Topics: Adolescent; Andersen Syndrome; Arrhythmias, Cardiac; Calcium Channel Blockers; Electrocardiography, | 2014 |
Effects of Na+ channel blockers on extrasystolic stimulation-evoked changes in ventricular conduction and repolarization.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrophysiological Pheno | 2014 |
Arrhythmogenic effects by local left ventricular stretch: effects of flecainide and streptomycin.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Blood Pressure; Flecainide; Heart Ventricles; | 2014 |
How are arrhythmias managed in the paediatric population in Europe? Results of the European Heart Rhythm survey.
Topics: Adolescent; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atenolol; Catheter Ablation; Child; Child, | 2014 |
Abnormal sodium current properties contribute to cardiac electrical and contractile dysfunction in a mouse model of myotonic dystrophy type 1.
Topics: Action Potentials; Aging; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Brugada Syndrome; C | 2015 |
Management of paediatric arrhythmias in Europe: authors' reply.
Topics: Arrhythmias, Cardiac; Atenolol; Catheter Ablation; Female; Flecainide; Humans; Male; Pacemaker, Arti | 2015 |
Management of paediatric arrhythmias in Europe.
Topics: Arrhythmias, Cardiac; Atenolol; Catheter Ablation; Female; Flecainide; Humans; Male; Pacemaker, Arti | 2015 |
Channel Activity of Cardiac Ryanodine Receptors (RyR2) Determines Potency and Efficacy of Flecainide and R-Propafenone against Arrhythmogenic Calcium Waves in Ventricular Cardiomyocytes.
Topics: Animals; Arrhythmias, Cardiac; Caffeine; Calcium; Calcium Signaling; Calsequestrin; Cell Membrane Pe | 2015 |
Flecainide-induced prolongation of ventricular repolarization contributes to the proarrhythmic profile of action.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Flecainide; Heart Conduction System; Heart Ventricles; | 2015 |
Molecular basis of hERG potassium channel blockade by the class Ic antiarrhythmic flecainide.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Flecainide; Gene Expression Regulation; HEK293 Cells; | 2015 |
Diagnostic Approach to Unexplained Cardiac Arrest (from the FIVI-Gen Study).
Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Brugada Syndrome; Cardiac Catheteri | 2015 |
Evaluation of Index of Cardio-Electrophysiological Balance (iCEB) as a New Biomarker for the Identification of Patients at Increased Arrhythmic Risk.
Topics: Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Biomarkers, Pharmacological; Brugada Syndrome; | 2016 |
Flecainide attenuates rate adaptation of ventricular repolarization in guinea-pig heart.
Topics: Action Potentials; Adaptation, Physiological; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; | 2016 |
Acute interstitial nephritis due to flecainide therapy in the 38(th) week of pregnancy.
Topics: Acute Disease; Acute Kidney Injury; Anti-Arrhythmia Agents; Anti-Inflammatory Agents, Non-Steroidal; | 2016 |
Effect of flecainide on suppression of ventricular fibrillation in a patient with early repolarization syndrome.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocardiography; Flecainide; Humans; Male; Ventric | 2016 |
Reply to the Editor- Effect of Flecainide on Suppression of Ventricular Fibrillation in a Patient With Early Repolarization Syndrome.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocardiography; Flecainide; Humans; Ventricular F | 2016 |
To the Editor-Flecainide and ventricular fibrillation in patients with early repolarization syndrome.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocardiography; Flecainide; Humans; Ventricular F | 2016 |
A human pluripotent stem cell model of catecholaminergic polymorphic ventricular tachycardia recapitulates patient-specific drug responses.
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Biomarkers; Calcium; Calcium Signaling; Catechola | 2016 |
Antiarrhythmic drug therapy in patients with arrhythmogenic dysplasia/cardiomyopathy: Is there a role for flecainide?
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Arrhythmogenic Right Ventricular Dysplasia; Cardiomyop | 2017 |
Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Calcium; Child; Flecainide; Heart Rate; Human | 2009 |
The organic cation transporter, OCTN1, expressed in the human heart, potentiates antagonism of the HERG potassium channel.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cation Transport Proteins; Electrophysiology; Ether-A- | 2009 |
Flecainide inhibits arrhythmogenic Ca2+ waves by open state block of ryanodine receptor Ca2+ release channels and reduction of Ca2+ spark mass.
Topics: Animals; Arrhythmias, Cardiac; Calcium; Calcium Channel Blockers; Calcium Signaling; Calcium-Binding | 2010 |
An antidote for calcium leak: targeting molecular arrhythmia mechanisms.
Topics: Animals; Antidotes; Arrhythmias, Cardiac; Calcium; Calcium Signaling; Calcium-Binding Proteins; Flec | 2010 |
Effects of flecainide and quinidine on action potential and ventricular arrhythmogenic properties in Scn3b knockout mice.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electric Stimulation; Endo | 2010 |
Pharmacological activation of IKr impairs conduction in guinea pig hearts.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Pacing, Artificial | 2010 |
Predicting drug-induced slowing of conduction and pro-arrhythmia: identifying the 'bad' sodium current blockers.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; CHO Cells; Cricetinae; Cricetulus; Drug Evalu | 2010 |
Flecainide-associated bradycardia-dependent torsade de pointes: another potential mechanism of proarrhythmia.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Bradycardia; Female; Flecainide; Humans; Torsade | 2013 |
Spatial and temporal heterogeneities are localized to the right ventricular outflow tract in a heterozygotic Scn5a mouse model.
Topics: Action Potentials; Algorithms; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Blood Pressure | 2011 |
Biophysical and molecular characterization of a novel de novo KCNJ2 mutation associated with Andersen-Tawil syndrome and catecholaminergic polymorphic ventricular tachycardia mimicry.
Topics: Amino Acid Sequence; Amino Acid Substitution; Andersen Syndrome; Arrhythmias, Cardiac; Base Sequence | 2011 |
Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Child; Defibrillators, Implan | 2011 |
The safety of flecainide treatment of atrial fibrillation: long-term incidence of sudden cardiac death and proarrhythmic events.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiovascular Agents; Coho | 2011 |
Refractory dispersion promotes conduction disturbance and arrhythmias in a Scn5a (+/-) mouse model.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Brugada Syndrome; Electric | 2011 |
A computational model to predict the effects of class I anti-arrhythmic drugs on ventricular rhythms.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Computer Simulation; Flecainide; Heart Conduc | 2011 |
Pediatric flecainide toxicity from a double dose.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocardiography; Emergency Service, Hospital; Flec | 2012 |
A novel method of fetal cardioversion.
Topics: Administration, Oral; Arrhythmias, Cardiac; Digoxin; Dose-Response Relationship, Drug; Drug Administ | 2013 |
Brugada electrocardiogram pattern induced by cannabis.
Topics: Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Brugada Syndrome; Cannabis; Electrocardiography | 2012 |
Flecainide-induced proarrhythmia is attributed to abnormal changes in repolarization and refractoriness in perfused guinea-pig heart.
Topics: Animals; Arrhythmias, Cardiac; Electrocardiography; Endocardium; Female; Flecainide; Guinea Pigs; In | 2012 |
A case of near-fatal flecainide overdose in a neonate successfully treated with sodium bicarbonate.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Drug Overdose; Flecainide; Humans; Infant, Newborn; Ma | 2013 |
A novel, potent, and selective inhibitor of cardiac late sodium current suppresses experimental arrhythmias.
Topics: Acetanilides; Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiotonic | 2013 |
ECG diagnosis: flecainide toxicity.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Drug-Related Side Effects and Adverse Reactions; Elect | 2012 |
Neonatal ECG changes caused by supratherapeutic flecainide following treatment for fetal supraventricular tachycardia.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocardiography; Female; Fetal Diseases; Flecainid | 2003 |
A newly characterized SCN5A mutation underlying Brugada syndrome unmasked by hyperthermia.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Bundle-Branch Block; Cholangitis; Death, Sudden, Cardi | 2003 |
Use of intravenous flecainide in horses with naturally-occurring atrial fibrillation.
Topics: Acute Disease; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Chronic D | 2004 |
Flecainide-induced neuropathy.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Flecainide; Gait Disorders, Neurologic; | 2005 |
Safe and effective pharmacologic management of arrhythmias.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocardiography; Flecainide; Humans; P | 2005 |
Oxidative mediated lipid peroxidation recapitulates proarrhythmic effects on cardiac sodium channels.
Topics: Aldehydes; Arrhythmias, Cardiac; Cell Line; Flecainide; Humans; Isoprostanes; Lipid Peroxidation; My | 2005 |
Actions of flecainide on susceptibility to phase-2 ventricular arrhythmias during infarct evolution in rat isolated perfused hearts.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disease Susceptibility; Drug Design; Flecaini | 2006 |
Diabetes mellitus reduces the antiarrhythmic effect of ion channel blockers.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Blood Pressure; Diabetes Mellitus; Diabetes M | 2006 |
[Be careful in using flecainide by hemodialyzed patients].
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Flecainide; Humans; Kidney Failure, Chronic; Mal | 2006 |
Flecainide cardiotoxicity precipitated by electrolyte imbalance. Caution with thiazide diuretics.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Bendroflumethiazide; Diuretics; Drug Interactions; Ele | 2007 |
Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disease Models, Animal; Do | 2007 |
New drugs in the management of ventricular arrhythmias.
Topics: Acecainide; Amiodarone; Anilides; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Benzeneac | 1984 |
[Effect of flecainide on chronic ventricular arrhythmias (author's transl)].
Topics: Adult; Anti-Arrhythmia Agents; Aortic Valve Stenosis; Arrhythmias, Cardiac; Cardiac Complexes, Prema | 1982 |
[Study of flecainide in the treatment of ventricular arrhythmia].
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; | 1983 |
Effect of the antiarrhythmic agent flecainide acetate on acute and chronic pacing thresholds.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Dose-Res | 1983 |
A double-blind, crossover comparison of flecainide acetate and disopyramide phosphate in the treatment of ventricular premature complexes.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Blood Pressure; Disopyramide; Double-Blin | 1984 |
The use of tocainide, encainide, lorcainide and flecainide for supraventricular arrhythmias.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrioventricular Node; | 1984 |
[Amiodarone-flecainide combination in the treatment of severe ventricular arrhythmia].
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzofurans; Drug Therapy, Combination; Fl | 1984 |
Flecainide: one-year efficacy in patients with chronic ventricular arrhythmias.
Topics: Adult; Aged; Arrhythmias, Cardiac; Chronic Disease; Dizziness; Drug Evaluation; Electrocardiography; | 1984 |
[Effect of intravenous flecainide in the treatment of acute ventricular arrhythmia].
Topics: Acute Disease; Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocardiog | 1983 |
Proarrhythmic effects of the new antiarrhythmic agent flecainide acetate.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrioventricular No | 1984 |
Flecainide toxicity.
Topics: Aged; Arrhythmias, Cardiac; Dose-Response Relationship, Drug; Flecainide; Heart Ventricles; Humans; | 1984 |
Symposium on flecainide acetate.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Flecainide; Humans; Piperidines | 1984 |
Extracardiac adverse effects of flecainide.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Dizziness; Dyspnea; Flecainide; Headache; Humans; Naus | 1984 |
Antiarrhythmic and electrophysiologic actions of flecainide in animal models.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disease Models, Animal; Do | 1984 |
Electrophysiologic effects of flecainide acetate on sinus node function, anomalous atrioventricular connections, and pacemaker thresholds.
Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrioventricular Node; Cardiac Paci | 1984 |
Flecainide dose-response relations in stable ventricular arrhythmias.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Dose-Response Relationship, Drug; Drug Ev | 1984 |
Flecainide: its proarrhythmic effect and expected changes on the surface electrocardiogram.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocardiography; Flecainide; Hemodynamics; Humans; | 1984 |
Oral flecainide for suppression of ventricular arrhythmias.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chronic Disease; Dr | 1984 |
Long-term antiarrhythmic therapy with flecainide.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Drug Evaluation; Female; Flecainide; Huma | 1984 |
Use of flecainide acetate in the treatment of premature ventricular contractions.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocardiography; Female; Flecainide; | 1983 |
Acute electrophysiological effects of flecainide acetate on cardiac conduction and refractoriness in man.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrophysiology; Female; Fl | 1982 |
[Anti-arrhythmia and antifibrillatory effect of flecainide in programmed ventricle stimulation and in recent heart infarction].
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Dogs; Flecainide; Heart Ventricles; Myocardia | 1982 |
[Antiarrhythmic therapy with flecainide in acute experimental myocardial infarction (author's transl)].
Topics: Animals; Arrhythmias, Cardiac; Dogs; Flecainide; Heart Rate; Hemodynamics; Myocardial Infarction; Ox | 1981 |
[Anti-arrhythmia effect of flecainide in acute myocardial infarct in comparison with lidocaine].
Topics: Acute Disease; Animals; Arrhythmias, Cardiac; Dogs; Flecainide; Lidocaine; Myocardial Infarction; Pi | 1981 |
[Electrophysiological effects of the new antiarrhythmic drug flecainide (R 818) in man (author's transl)].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Blood Pressure; Electrocardiography; Fema | 1981 |
Clinical electrophysiologic study of antiarrhythmic properties of flecainide: acute intraventricular delayed conduction and prolonged repolarization in regular paced and premature beats using intracardiac monophasic action potentials with programmed stimu
Topics: Action Potentials; Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Blood Pressure; Cardiac Paci | 1981 |
Suppression of resistant ventricular arrhythmias by twice daily dosing with flecainide.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Dose-Response Relationship, Drug; Drug Re | 1981 |
Antiarrhythmic effects of flecainide.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocardiography; Female; Flecainide; | 1980 |
Antiarrhythmic effects of bisaramil on triggered arrhythmias produced by intracoronary injection of digitalis and adrenaline in the dog.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Bridged Bicyclo Compounds, Heterocyclic; Chlo | 1995 |
Use- and concentration-dependent effects of flecainide in guinea pig right ventricular muscle.
Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Dose-Response Relationship, Drug; Female; Flecaini | 1994 |
Effects of flecainide and D-sotalol on myocardial conduction and refractoriness: relation to antiarrhythmic and proarrhythmic drug effects.
Topics: Animals; Arrhythmias, Cardiac; Dogs; Electric Stimulation; Electrocardiography; Electrophysiology; F | 1993 |
Electrophysiological effects of flecainide on anisotropic conduction and reentry in infarcted canine hearts.
Topics: Animals; Anisotropy; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Dogs; Electrocardiography; El | 1995 |
Frequency dependent effects of class I antiarrhythmic agents studied in patients with implanted pacemakers.
Topics: Aged; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Cross-Ove | 1994 |
Reentrant arrhythmias in the subacute infarction period. The proarrhythmic effect of flecainide acetate on functional reentrant circuits.
Topics: Animals; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Death, Sudden, Cardiac; Dogs; Electrocard | 1995 |
Flecainide acetate: concentration-response relationships for antiarrhythmic and electrocardiographic effects.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Dose-Response Relat | 1993 |
Effect of E-4031, a new class III antiarrhythmic drug, on reentrant ventricular arrhythmias: comparison with conventional class I drugs.
Topics: Animals; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Disease Models, Animal; Disopyrami | 1993 |
[Effective dose of flecainide for arrhythmia in children].
Topics: Administration, Oral; Adolescent; Arrhythmias, Cardiac; Child; Child, Preschool; Electrocardiography | 1993 |
Arrhythmogenicity of antiarrhythmic drugs and intraventricular conduction disorders: possible aggravation by myocardial ischemia--study in the porcine in situ heart.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disease Models, Animal; Electrocardiography; | 1993 |
Comparative efficacy of antiarrhythmic agents in preventing halothane-epinephrine arrhythmias in rats.
Topics: Amiodarone; Anesthesia, Inhalation; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Epinephri | 1993 |
Flecainide-induced arrhythmia in canine ventricular epicardium. Phase 2 reentry?
Topics: 4-Aminopyridine; Action Potentials; Animals; Arrhythmias, Cardiac; Dogs; Endocardium; Flecainide; He | 1993 |
Comparative study on the proarrhythmic effects of some antiarrhythmic agents.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Dose-Response Relationship, Drug; Electrocard | 1993 |
Proarrhythmic actions of flecainide in an isolated tissue model of ischemia and reperfusion.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Flecainide; Guinea Pigs; H | 1996 |
Flecainide and the electrophysiologic matrix: the effects of flecainide acetate on the determinants of cardiac excitability in sheep Purkinje fibers.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Flecainide; Hyperkalemia; | 1996 |
Safety and efficacy of oral flecainide acetate in patients with cardiac arrhythmias.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Child; | 1997 |
ST segment elevation induced by class IC antiarrhythmic agents: underlying electrophysiologic mechanisms and insights into drug-induced proarrhythmia.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiomyopathy, Dilated; Electroc | 1998 |
Effects of an antiarrhythmic drug A-2545 on canine ventricular arrhythmia models; comparison with mexiletine and flecainide.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Blood Pressure; Coronary Vessels; Dogs; Dose- | 1998 |
Intracoronary flecainide induces ST alternans and reentrant arrhythmia on intact canine heart: A role of 4-aminopyridine-sensitive current.
Topics: 4-Aminopyridine; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Coronary Vessels; Disopyrami | 1999 |
A critical appraisal of the cardiac arrhythmia suppression trial (CAST).
Topics: Arrhythmias, Cardiac; Clinical Trials as Topic; Encainide; Flecainide; Humans; Imipramine; Moricizin | 1991 |
Relation between activation sequence fluctuation and arrhythmogenicity in sodium-channel blockades.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Dogs; Flecainide; Heart; Sodium Channel Block | 1999 |
Effects of ambasilide, quinidine, flecainide and verapamil on ultra-rapid delayed rectifier potassium currents in canine atrial myocytes.
Topics: Aminobenzoates; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Bridged Bicyclo Compounds, He | 2000 |
Anisotropic effects of sodium channel blockers on the wavelength for ventricular excitation in dogs.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disopyramide; Dogs; Electr | 2000 |
Choreic movements induced by cibenzoline: an Ic class antiarrhythmic effect?
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chorea; Dopamine Antagonists; Dyskinesia, Drug-I | 2000 |
ST segment elevation in the right precordial leads following administration of class Ic antiarrhythmic drugs.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Electrocardiography; Female | 2001 |
[Fetal arrhythmias: diagnosis, prognosis, treatment; apropos of 33 cases].
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Bradycardia; Cardiac Complexes, Premature; Echocardiog | 2000 |
Gating-dependent mechanisms for flecainide action in SCN5A-linked arrhythmia syndromes.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cell Line; Electrocardiography; Flecainide; Green Fluo | 2001 |
Flecainide widens the excitable gap at pivot points of premature turning wavefronts in rabbit ventricular myocardium.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Catheter Ablation; Electrocardiography; Femal | 2001 |
Limited antifibrillatory effectiveness of clinically relevant concentrations of class I antiarrhythmics in isolated perfused rat hearts.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Coronary Circulation; Electrocardiography; Fl | 2002 |
Channel openings are necessary but not sufficient for use-dependent block of cardiac Na(+) channels by flecainide: evidence from the analysis of disease-linked mutations.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cell Line; Flecainide; Humans; Long QT Syndrome; Mutat | 2002 |
A proarrhythmic response to sodium channel blockade: modulation of the vulnerable period in guinea pig ventricular myocardium.
Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Flecainide; Guinea Pigs; Heart; In Vitro Technique | 1992 |
[Anti-arrhythmia agents in heart failure].
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; C | 1992 |
Flecainide in quinidine-resistant atrial fibrillation.
Topics: Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Drug Therapy, Combination; Electrocardiograph | 1992 |
Effects of flecainide on ventricular arrhythmias, abnormal automaticity and activation in a canine model of myocardial infarction.
Topics: Animals; Arrhythmias, Cardiac; Disease Models, Animal; Dogs; Electrocardiography; Flecainide; Heart | 1992 |
Stereoselective genetically-determined interaction between chronic flecainide and quinidine in patients with arrhythmias.
Topics: Arrhythmias, Cardiac; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Drug Interactions; Fl | 1992 |
Flecainide for supraventricular tachyarrhythmias.
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Flecainide; Humans; Tachycardia, Paroxysmal; Tachycardia, | 1992 |
Flecainide-associated interstitial pneumonitis.
Topics: Acute Disease; Arrhythmias, Cardiac; Flecainide; Humans; Male; Middle Aged; Pulmonary Fibrosis; Resp | 1991 |
Oral flecainide for the treatment of drug-resistant ventricular ectopy.
Topics: Administration, Oral; Adult; Aged; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Drug Evaluati | 1990 |
Proarrhythmic and antiarrhythmic effects of flecainide on nonsustained reentry around the canine atrial tricuspid ring in vitro.
Topics: Animals; Arrhythmias, Cardiac; Dogs; Flecainide; Heart Conduction System; Humans; Tachycardia | 1991 |
The spectrum of CAST I and II.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Death, Sudden, Cardiac; | 1991 |
Increased susceptibility to reentrant arrhythmias by flecainide.
Topics: Arrhythmias, Cardiac; Disease Susceptibility; Flecainide; Humans | 1992 |
Crime, misdemeanor, and arrhythmia decoding CAST.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden, Cardiac; Encainide; Flecainide; Heart V | 1991 |
Antiarrhythmic and cardiovascular profiles of the fused indole compound (3aR,12R,12aR,12bS)-12-amino-2,3,3a,4,11,12,12a,12b-octahydro-10-hydrox yisoquino [2,1,8-lma]carbazol-5(1H)-one hydrochloride 1.5 hydrate.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Carbazoles; Chloroform; Disopyramide; Dogs; F | 1991 |
Effects of Org 7797 on early, late and inducible arrhythmias following coronary artery occlusion in rats and dogs.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Dogs; Electric Stimulation; Estrenes; Female; | 1991 |
Heart rate variability in patients with ventricular arrhythmias: effect of antiarrhythmic drugs. Antiarrhythmic Drug Evaluation Group (ADEG).
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocar | 1991 |
Mortality in patients treated with flecainide and encainide for supraventricular arrhythmias.
Topics: Adult; Aged; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Encainide; Female; Flecainide; | 1991 |
Proarrhythmia, cardiac arrest and death in young patients receiving encainide and flecainide. The Pediatric Electrophysiology Group.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Child; Death, Sudden; Encainide; Flecainide; | 1991 |
Encainide and flecainide in children: separating the wheat from the chaff.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Child; Encainide; Flecainide; Humans; Risk F | 1991 |
[Arrhythmogenic risk of antiarrhythmic drugs: study with class Ic drugs during myocardial ischemia].
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Coronary Disease; | 1991 |
Proarrhythmic effects of flecainide. Experimental evidence for increased susceptibility to reentrant arrhythmias.
Topics: Animals; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Flecainide; Heart Conduction System; In V | 1991 |
The healthy responder phenomenon in non-randomized clinical trials. CAST Investigators.
Topics: Arrhythmias, Cardiac; Clinical Trials as Topic; Data Interpretation, Statistical; Double-Blind Metho | 1991 |
Flecainide acetate in atrial flutter and fibrillation. The arrhythmogenic effects.
Topics: Aged; Aged, 80 and over; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Flecainide; Huma | 1990 |
[Effects of oral flecainide treatment of refractory tachyarrhythmias].
Topics: Administration, Oral; Adult; Arrhythmias, Cardiac; Drug Evaluation; Electrocardiography; Female; Fle | 1990 |
Late proarrhythmia and understanding the time of occurrence of proarrhythmia.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Encainide; Flecainide; Humans | 1990 |
Inefficacy and proarrhythmic effects of flecainide and encainide for sustained ventricular tachycardia and ventricular fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrophysi | 1990 |
Physician attitudes toward the use of type IC antiarrhythmics after the Cardiac Arrhythmia Suppression Trial (CAST).
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Attitude of Health Personnel; Drug Utilizati | 1990 |
Treatment of ventricular arrhythmias in children without structural heart disease with class IC agents as guided by invasive electrophysiology.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Child; Electroph | 1990 |
The cardiac arrhythmia suppression trial: implications for antiarrhythmic drug development.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Drug Evaluation; E | 1990 |
Antiarrhythmic therapy--conventional wisdom challenged.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Encainide; Flecainide; Humans | 1990 |
Serious interactions of sotalol with amiodarone and flecainide.
Topics: Aged; Amiodarone; Arrhythmias, Cardiac; Drug Administration Schedule; Drug Interactions; Drug Therap | 1990 |
Flecainide acetate dose-concentration relationship in cardiac arrhythmias: influence of heart failure and amiodarone.
Topics: Adult; Aged; Amiodarone; Arrhythmias, Cardiac; Body Weight; Dose-Response Relationship, Drug; Drug I | 1990 |
Pacing failure due to flecainide acetate.
Topics: Aged; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Flecainide; Humans; Male; Piperidines; Tachy | 1985 |
Flecainide: a new antiarrhythmic agent.
Topics: Arrhythmias, Cardiac; Cardiac Complexes, Premature; Dizziness; Electrophysiology; Flecainide; Hemody | 1986 |
Electrophysiological effects of flecainide on guinea pig ventricular muscle in high [K+]o, acidosis and hypoxia.
Topics: Acidosis; Action Potentials; Animals; Arrhythmias, Cardiac; Coronary Disease; Female; Flecainide; Gu | 1987 |
[Kinetics of intravenously administered flecainide in patients with acute myocardial infarct].
Topics: Adult; Aged; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Female; Flecainide; Heart Ventricle | 1989 |
Drugs for cardiac arrhythmias: new warning.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Encainide; Flecainide; Humans | 1989 |
From the Food and Drug Administration.
Topics: Allergens; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Child; Drug Prescriptions; Encain | 1989 |
Efficacy and safety of flecainide in low-risk patients with chronic ventricular arrhythmias: a two-year follow-up.
Topics: Adult; Aged; Arrhythmias, Cardiac; Chronic Disease; Electrocardiography; Exercise Test; Female; Flec | 1989 |
Flecainide acetate for resistant arrhythmias in the young: efficacy and pharmacokinetics.
Topics: Administration, Oral; Adolescent; Adult; Arrhythmias, Cardiac; Child; Child, Preschool; Digoxin; Ech | 1989 |
[The effect of flecainide on 2 hour occlusion-induced myocardial damages in dog].
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Dogs; Flecainide; Heart Arrest, Induced; Lyso | 1989 |
The cardiac arrhythmia suppression trial (CAST).
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden; Encainide; Flecainide; Humans | 1989 |
[Supraventricular tachyarrhythmia of recent onset in the absence of documented cardiac pathology: different therapeutic approaches].
Topics: Aged; Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Electric Countershock; | 1989 |
A dual model for cardiac arrhythmias: coexistence of re-entry and abnormal automaticity and effects of antiarrhythmic agents.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disease Models, Animal; Dogs; Female; Flecain | 1989 |
Antiarrhythmic effects of the class 1c antiarrhythmic drug, flecainide, on canine ventricular arrhythmia models.
Topics: Animals; Arrhythmias, Cardiac; Coronary Vessels; Disease Models, Animal; Dogs; Epinephrine; Flecaini | 1989 |
[Value of transesophageal auricular stimulation for evaluating the accessory pathway and effect of treatment in Wolf-Parkinson-White syndrome].
Topics: Adult; Arrhythmias, Cardiac; Electric Stimulation; Electrocardiography; Female; Flecainide; Heart At | 1989 |
Electrophysiological effects of flecainide in a canine 7 day old myocardial infarction model.
Topics: Animals; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Disease Models, Animal; Dogs; Electrocard | 1989 |
[A case of atrial paralysis during the use of intravenous flecainide acetate].
Topics: Aged; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Electrocardiography; Female; Flecai | 1989 |
[Short- and medium-term treatment of ventricular hyperkinetic arrhythmia with flecainide].
Topics: Aged; Arrhythmias, Cardiac; Electrocardiography; Female; Flecainide; Follow-Up Studies; Humans; Male | 1989 |
The cardiac arrhythmia suppression trial.
Topics: Aged; Anilides; Arrhythmias, Cardiac; Encainide; Flecainide; Humans; Male | 1989 |
Amplification of flecainide-induced ventricular conduction slowing by exercise. A potentially significant clinical consequence of use-dependent sodium channel blockade.
Topics: Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Electrocardiography; Exercise; Exercise Test; Fema | 1989 |
Hypertonic sodium bicarbonate partially reverses QRS prolongation due to flecainide in rats.
Topics: Animals; Arrhythmias, Cardiac; Bicarbonates; Blood Pressure; Electrocardiography; Flecainide; Heart; | 1989 |
Indications for flecainide.
Topics: Arrhythmias, Cardiac; Flecainide; Humans | 1989 |
Indications for flecainide.
Topics: Arrhythmias, Cardiac; Flecainide; Humans | 1989 |
[Psoriasis-like eruption caused by flecainide].
Topics: Aged; Aged, 80 and over; Arrhythmias, Cardiac; Diagnosis, Differential; Drug Eruptions; Flecainide; | 1988 |
[Severe proarrhythmic effects of flecainide].
Topics: Aged; Arrhythmias, Cardiac; Electrocardiography; Female; Flecainide; Humans | 1988 |
Flecainide: a new antiarrhythmic agent.
Topics: Animals; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Electrophysiology; Flecainide; Heart; Hem | 1986 |
Dysarthria and visual hallucinations due to flecainide toxicity.
Topics: Aged; Arrhythmias, Cardiac; Dysarthria; Flecainide; Hallucinations; Humans; Male; Speech Disorders | 1986 |
Treatment of refractory supraventricular arrhythmias with flecainide acetate.
Topics: Administration, Oral; Adolescent; Arrhythmias, Cardiac; Child; Child, Preschool; Female; Flecainide; | 1987 |
Risk factors for the development of proarrhythmic events.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Encainide; Flecainide; Hospitalization; Huma | 1987 |
Efficacy and safety of flecainide acetate for atrial tachycardia or fibrillation.
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Flecainide; Heart Atria; Heart Ventricles; Humans; Tachyc | 1987 |
Plasma flecainide concentrations following acute myocardial infarction.
Topics: Administration, Oral; Aged; Arrhythmias, Cardiac; Female; Flecainide; Humans; Male; Middle Aged; Myo | 1987 |
[Oral flecainide in the treatment of refractory arrhythmias. Long-term follow-up of 98 patients].
Topics: Adult; Aged; Arrhythmias, Cardiac; Electrocardiography; Exercise Test; Female; Flecainide; Heart Fun | 1987 |
Antiarrhythmic efficacy of penticainide and comparison with disopyramide, flecainide, propafenone and mexiletine by acute oral drug testing.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chronic Disease; Di | 1987 |
Assessment of drug effects on spontaneous and induced ventricular arrhythmias in a 24-h canine infarction model.
Topics: Anilides; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disopyramide; Dogs; Electrocardiogr | 1987 |
[Concentrations of amiodarone and flecainide in plasma and saliva--indications for the active transport of flecainide].
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Arrhythmias, Cardiac; Biological Transport, Active; Fema | 1988 |
The development and testing of intravenous dosing regimens: application to flecainide for the suppression of ventricular arrhythmias.
Topics: Adult; Aged; Arrhythmias, Cardiac; Female; Flecainide; Humans; Infusions, Intravenous; Male; Middle | 1988 |
Flecainide half-life prolongation in 2 patients with congestive heart failure and complex ventricular arrhythmias.
Topics: Aged; Arrhythmias, Cardiac; Flecainide; Half-Life; Heart Failure; Humans; Middle Aged | 1988 |
Use of flecainide acetate in the treatment of supraventricular tachyarrhythmias.
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Flecainide; Humans; Tachycardia, Paroxysm | 1988 |
[Worsening of ventricular arrhythmia in the dynamic ECG in patients treated with anti-arrhythmia drugs].
Topics: Adolescent; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Drug Therapy, Com | 1988 |
Flecainide-induced cardiogenic shock.
Topics: Aged; Aged, 80 and over; Arrhythmias, Cardiac; Flecainide; Humans; Male; Shock, Cardiogenic | 1988 |
[Anomalies of the T waves induced by flecainide].
Topics: Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Drug Administration Schedule; Electrocardiogra | 1988 |
[QT prolongation and induction of torsades de pointe by flecainide. Apropos of a case].
Topics: Aged; Arrhythmias, Cardiac; Electrocardiography; Female; Flecainide; Humans; Tachycardia | 1988 |
Experience with flecainide for the treatment of cardiac arrhythmias in children.
Topics: Adolescent; Age Factors; Arrhythmias, Cardiac; Child; Child, Preschool; Female; Flecainide; Humans; | 1988 |
[An electrophysiologic study on the anti-ischemic arrhythmia effect of flecainide].
Topics: Animals; Arrhythmias, Cardiac; Dogs; Electrophysiology; Flecainide; Myocardial Infarction | 1988 |
[Clinical pharmacology of flecainide].
Topics: Arrhythmias, Cardiac; Drug Evaluation; Flecainide; Heart Conduction System; Hemodynamics; Humans | 1988 |
[New antiarrhythmia agents: propafenone and flecainide].
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocardiography; Electrophysiology; Flecainide; He | 1985 |
Flecainide: steady state electrophysiologic effects in patients with remote myocardial infarction and inducible sustained ventricular arrhythmia.
Topics: Adult; Aged; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Electrocardiography; Female; Flecaini | 1986 |
Treatment of resistant ventricular tachycardia with flecainide acetate. Flecainide Ventricular Tachycardia Study Group.
Topics: Arrhythmias, Cardiac; Electrocardiography; Female; Flecainide; Humans; Male; Middle Aged; Piperidine | 1986 |
Pharmacodynamics and side effects of flecainide acetate.
Topics: Aged; Arrhythmias, Cardiac; Cardiovascular Diseases; Dose-Response Relationship, Drug; Electrocardio | 1986 |
New antiarrhythmic agents.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Flecainide; Humans; Kinetics; Mexiletine; | 1986 |
[Value of flecainide in supraventricular arrhythmias].
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial F | 1986 |
Classification by type of ventricular arrhythmia predicts frequency of adverse cardiac events from flecainide.
Topics: Arrhythmias, Cardiac; Death, Sudden; Drug Administration Schedule; Flecainide; Heart Failure; Humans | 1986 |
Aggravation of ventricular arrhythmia. A drug-induced complication.
Topics: Anilides; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Disopyramide; Drug Evaluation; El | 1985 |
Short- and long-term experience with flecainide acetate in the management of refractory life-threatening ventricular arrhythmias.
Topics: Adolescent; Adult; Aged; Arrhythmias, Cardiac; Electrophysiology; Female; Flecainide; Follow-Up Stud | 1985 |
Flecainide: a new antiarrhythmic drug.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Flecainide; Heart Ventricles; Humans; Piperidines | 1986 |
Antiarrhythmic drug efficacy at electrophysiology testing: predictive effectiveness of procainamide and flecainide.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Exercise Test; Female; Fle | 1986 |
Flecainide and amiodarone interaction.
Topics: Adult; Aged; Amiodarone; Arrhythmias, Cardiac; Benzofurans; Drug Interactions; Female; Flecainide; H | 1986 |
Effects of flecainide on the electrophysiologic properties of isolated canine and rabbit myocardial fibers.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Calcium; Dogs; Electrophys | 1985 |
Flecainide-induced aggravation of ventricular arrhythmias.
Topics: Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocardiography; Female; Flecainide; Humans | 1985 |
Therapy of tachyarrhythmias, benefits and risks. Proceedings of a symposium. Düsseldorf, 11 July 1984.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Flecainide; Humans; Piperidines | 1985 |
Effect of intravenous flecainide on atrial vulnerability in man.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Flutter; Electrocardio | 1985 |
Experience in the long term use of new antiarrhythmic drugs.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Flecainide; Humans; Male; Middle | 1985 |
The clinical use of oral flecainide.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Flecainide; Humans; Piperidines; | 1985 |
The proarrhythmic effects of flecainide.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocardiography; Female; Flecainide; | 1985 |
Haemodynamic and antiarrhythmic effects of intravenous flecainide acetate in chronic congestive heart failure.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chronic Disease; Electrocardiography; Flecainide; Hear | 1985 |
Clinical usefulness of flecainide acetate in the treatment of paroxysmal supraventricular arrhythmias.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocardiography; Flecainide; Guinea Pigs; | 1985 |
Antiarrhythmic therapy with flecainide in combination and comparison with propranolol.
Topics: Adult; Aged; Arrhythmias, Cardiac; Drug Therapy, Combination; Electrocardiography; Female; Flecainid | 1985 |
[Evaluation of flecainide in the therapy of chronic ventricular arrhythmia using the acute oral load method].
Topics: Administration, Oral; Adult; Aged; Arrhythmias, Cardiac; Chronic Disease; Female; Flecainide; Heart | 1985 |
[Flecainide in the treatment of chronic ventricular arrhythmia].
Topics: Arrhythmias, Cardiac; Chronic Disease; Flecainide; Heart Ventricles; Humans; Piperidines | 1985 |
Conversion of supraventricular arrhythmias to sinus rhythm using flecainide.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Flecainide; Heart Rate; Humans; M | 1985 |